

Douglas L. Mayers · Jack D. Sobel  
Marc Ouellette · Keith S. Kaye  
Dror Marchaim *Editors*

# Antimicrobial Drug Resistance

Clinical and Epidemiological Aspects,  
Volume 2

*Second Edition*

 Springer

---

# Antimicrobial Drug Resistance

---

Douglas L. Mayers • Jack D. Sobel  
Marc Ouellette • Keith S. Kaye • Dror Marchaim  
Editors

# Antimicrobial Drug Resistance

Clinical and Epidemiological Aspects,  
Volume 2

Second Edition

 Springer

*Editors*

Douglas L. Mayers, M.D.  
Chief Medical Officer  
Treiber Therapeutics  
Cambridge, MA, USA

Marc Ouellette, Ph.D.  
Professor  
Canada Research Chair in Antimicrobial Resistance  
Centre de recherche en Infectiologie  
University of Laval  
Quebec City, Canada

Dror Marchaim, M.D.  
Infection Control and Prevention  
Unit of Infectious Diseases  
Assaf Harofeh Medical Center  
Sackler Faculty of Medicine  
Tel-Aviv University  
Tel Aviv, Israel

Jack D. Sobel, M.D.  
Professor of Medicine  
Dean, Wayne State University School  
of Medicine  
Detroit Medical Center  
Detroit, MI, USA

Keith S. Kaye, M.D., M.P.H.  
Professor of Internal Medicine  
Director of Clinical Research, Division  
of Infectious Diseases  
University of Michigan Medical School  
Ann Arbor, MI, USA

ISBN 978-3-319-47264-5      ISBN 978-3-319-47266-9 (eBook)  
DOI 10.1007/978-3-319-47266-9

Library of Congress Control Number: 2017930150

© Springer International Publishing AG 2009, 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature  
The registered company is Springer International Publishing AG Switzerland  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

---

## Preface

Antimicrobial drug resistance is a global health problem that continues to expand as micro-organisms adapt to the antibiotics we use to treat them and as new classes of antimicrobial agents have been harder to discover and advance into the clinic. The second edition of *Antimicrobial Drug Resistance* grew out of a desire by the editors and authors to provide an updated, comprehensive resource of information on antimicrobial drug resistance that would encompass the current information available for bacteria, fungi, protozoa, and viruses. The two volumes have been extensively revised with many new authors and chapters as the field of drug resistance has evolved. We believe that this information will be of value to clinicians, epidemiologists, microbiologists, virologists, parasitologists, public health authorities, medical students, and fellows in training. We have endeavored to provide this information in a style that is accessible to the broad community of persons who are concerned with the impact of drug resistance in our clinics and across broader global communities.

*Antimicrobial Drug Resistance* is divided into two volumes. Volume 1 has sections covering a general overview of drug resistance and mechanisms of drug resistance, first for classes of drugs and then by individual antimicrobial agents, including those targeting bacteria, fungi, protozoa, and viruses. Volume 2 addresses clinical, epidemiologic, and public health aspects of drug resistance, along with an overview of the conduct and interpretation of specific drug resistance assays. Together, these two volumes offer a comprehensive source of information on drug resistance issues by the experts in each topic.

We are very grateful to the 197 international experts who have contributed to this textbook for their patience and support as the work came together. The editors would like to especially thank Michelle Feng He for her exceptional support and encouragement to the editors in bringing this revised textbook to print. Finally, the book would never have been completed without the patience and support of our wives and families.

Cambridge, MA, USA  
Detroit, MI, USA  
Québec, Canada  
Ann Arbor, MI, USA  
Tel Aviv, Israel

Douglas L. Mayers, M.D.  
Jack D. Sobel, M.D.  
Marc Ouellette, M.D.  
Keith S. Kaye, M.D., M.P.H.  
Dror Marchaim, M.D.

---

## Contents

### Part VII Gram Positive Bacterial Drug Resistance: Clinical

- 49 **Resistance in *Streptococcus pneumoniae*** ..... 777  
Lesley McGee and Keith P. Klugman
- 50 **Antibiotic Resistance of Non-pneumococcal Streptococci  
and Its Clinical Impact** ..... 791  
Nainee Desai, Judith Steenbergen, and David E. Katz
- 51 **Enterococcal Infections in Adults** ..... 811  
Katherine Reyes, Marcus Zervos, and Jisha John
- 52 **Antimicrobial Resistance in *Staphylococci aureus*: Mechanisms  
of Resistance and Clinical Significance** ..... 819  
Donald P. Levine and Jisha John
- 53 **Resistance in Aerobic Gram-Positive *Bacilli*** ..... 827  
David J. Weber, Melissa B. Miller, and William A. Rutala

### Part VIII Gram Negative Bacterial Drug Resistance: Clinical

- 54 **Antibiotic Resistance in *Neisseria*** ..... 843  
Margaret C. Bash and Kathryn A. Matthias
- 55 **Mechanisms of Resistance in *Haemophilus influenzae*  
and *Moraxella catarrhalis*** ..... 867  
Michael R. Jacobs
- 56 **Enterobacteriaceae** ..... 889  
David L. Paterson and Yohei Doi
- 57 ***Pseudomonas*** ..... 899  
Kamilia Abdelraouf and Vincent H. Tam
- 58 ***Acinetobacter baumannii* and *Acinetobacter* spp.** ..... 923  
Federico Perez and Robert A. Bonomo
- 59 **Antimicrobial Resistance in *Stenotrophomonas maltophilia*:  
Mechanisms and Clinical Implications** ..... 937  
Xian-Zhi Li and Jennifer Li
- 60 **Antimicrobial Resistance of *Shigella* spp., Typhoid *Salmonella*,  
and Non-typhoid *Salmonella*** ..... 959  
Herbert L. DuPont and Jean M. Whichard
- 61 **Antimicrobial Resistance in *Vibrio*** ..... 969  
Michael L. Bennish, Wasif A Khan, and Sabeena Ahmed

<b>62</b>	<b>Antimicrobial Resistance in <i>Helicobacter</i> and <i>Campylobacter</i> .....</b>	<b>991</b>
	Patrick F. McDermott and Francis Mégraud	
<b>63</b>	<b>Antimicrobial Resistance of Anaerobic Bacteria .....</b>	<b>1007</b>
	Itzhak Brook	
<b>64</b>	<b>Mycobacteria: Tuberculosis .....</b>	<b>1041</b>
	Akos Somoskovi and Max Salfinger	
<b>65</b>	<b>Drug Resistance of Non-tuberculous Mycobacteria .....</b>	<b>1061</b>
	Kathleen L. Horan and Gerard A. Cangelosi	
<b>Part IX Fungal Drug Resistance: Clinical</b>		
<b>66</b>	<b>The Role of Resistance in <i>Candida</i> Infections: Epidemiology and Treatment.....</b>	<b>1075</b>
	Jack D. Sobel and R.A. Akins	
<b>67</b>	<b>Antifungal Drug Resistance in <i>Aspergillus</i> .....</b>	<b>1099</b>
	P.H. Chandrasekar and Elias K. Manavathu	
<b>68</b>	<b>Drug Resistance in Cryptococcosis.....</b>	<b>1119</b>
	Kimberly E. Hanson, Jelena Catania, Barbara D. Alexander, and John R. Perfect	
<b>69</b>	<b>Antifungal Therapy for Histoplasmosis: Focus on Susceptibility, Resistance, and Effectiveness in Humans and Experimental Infection .....</b>	<b>1141</b>
	L. Joseph Wheat	
<b>70</b>	<b>Drug Resistance in <i>Pneumocystis jirovecii</i> .....</b>	<b>1147</b>
	Jannik Helweg-Larsen, Thomas Benfield, Joseph Kovacs, and Henry Masur	
<b>Part X Viral Drug Resistance: Clinical</b>		
<b>71</b>	<b>Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects.....</b>	<b>1165</b>
	Erhard van der Vries and Michael G. Ison	
<b>72</b>	<b>Herpesvirus Resistance to Antiviral Drugs.....</b>	<b>1185</b>
	Jocelyne Piret and Guy Boivin	
<b>73</b>	<b>Clinical Implications of HIV-1 Drug Resistance .....</b>	<b>1213</b>
	Douglas L. Mayers and John D. Baxter	
<b>74</b>	<b>Hepatitis B Virus Drug Resistance .....</b>	<b>1227</b>
	Apostolos Beloukas and Anna Maria Geretti	
<b>Part XI Parasitic Drug Resistance: Clinical</b>		
<b>75</b>	<b>Antimalarial Drug Resistance: Clinical Perspectives.....</b>	<b>1245</b>
	Bruno Pradines	
<b>76</b>	<b>Diagnosis and Treatment of Metronidazole-Resistant <i>Trichomonas vaginalis</i> Infection.....</b>	<b>1277</b>
	Jeffrey D. Smith, Sarah L. Cudmore, and Gary E. Garber	
<b>77</b>	<b>Drug Resistance in Leishmaniasis .....</b>	<b>1293</b>
	Shyam Sundar and Jaya Chakravarty	

<b>78 Occurrence, Measurement and Clinical Perspectives of Drug Resistance in Important Parasitic Helminths of Livestock.....</b>	<b>1305</b>
R.G. Woodgate, A.J. Cornell, and N.C. Sangster	
<b>Part XII Measurements of Drug Resistance</b>	
<b>79 In Vitro Performance and Analysis of Combination Anti-infective Evaluations .....</b>	<b>1329</b>
Robert W. Buckheit Jr. and R. Dwayne Lunsford	
<b>80 Antimicrobial Susceptibility Testing Methods for Bacterial Pathogens .....</b>	<b>1347</b>
Fred C. Tenover	
<b>81 Drug Resistance Assays for <i>Mycobacterium tuberculosis</i>.....</b>	<b>1359</b>
Sebastian G. Kurz and Max Salfinger	
<b>82 Fungal Drug Resistance Assays .....</b>	<b>1367</b>
Sevtap Arikan-Akdagli and John H. Rex	
<b>83 Viral Phenotypic Resistance Assays .....</b>	<b>1389</b>
Jacqueline D. Reeves and Neil T. Parkin	
<b>84 Drug Resistance Assays for Parasitic Diseases .....</b>	<b>1409</b>
Danielle Légaré and Marc Ouellette	
<b>85 Bacterial Genotypic Drug Resistance Assays .....</b>	<b>1465</b>
A. Huletsky and Michel G. Bergeron	
<b>86 Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases .....</b>	<b>1501</b>
Ying-Shan Han and Mark A. Wainberg	
<b>Part XIII Public Health Issues of Drug Resistance</b>	
<b>87 Antimicrobial Resistance: An International Public Health Problem.....</b>	<b>1519</b>
Joseph D. Lutgring, Carlos A. Diaz Granados, and John E. McGowan Jr.	
<b>88 Hospital Infection Control: Considerations for the Management and Control of Drug-Resistant Organisms.....</b>	<b>1529</b>
Summer Donovan and Gonzalo M.L. Bearman	
<b>89 Controlling the Spread of Resistant Pathogens in the Intensive Care Unit.....</b>	<b>1551</b>
Tara N. Palmore and David K. Henderson	
<b>90 Implications of Antibiotic Resistance in Potential Agents of Bioterrorism .....</b>	<b>1565</b>
Linda M. Weigel and Stephen A. Morse	
<b>91 Internet Resources on Antimicrobial Resistance .....</b>	<b>1593</b>
Matthew E. Falagas and Kyriakos K. Triggidis	
<b>Index.....</b>	<b>1599</b>



---

## Contributors

**Kamilia Abdelraouf** Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

**Sabeena Ahmed, M.Sc.** Senior Research Officer, Infectious Disease Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

**Robert A. Akins, Ph.D.** Professor of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, MI, USA

**Barbara D. Alexander, M.D.** Professor of Medicine and Pathology, Duke University, Durham, NC, USA

**Elizabeth R. Andrews, Pharm.D.** Clinical Scientist, G1 Therapeutics, Research Triangle Park, NC, USA

**Sevtap Arikan-Akdagli, M.D.** Professor of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, Turkey

Director, Mycology Laboratory, Hacettepe University Medical School, Ankara, Turkey

**Eric J. Arts, Ph.D.** Professor of Microbiology and Immunology, Canada Research Chair on HIV Pathogenesis and Viral Control, University of Western Ontario, London, ON, Canada

**Dominique Aubert, Ph.D.** Laboratory Parasitology-Mycology, Hospital Maison Blanche and EA 3800, University of Reims Champagne-Ardenne, Reims, France

**Fernando Baquero, M.D., Ph.D.** Research Professor, Biology and Evolution of Microorganisms, Ramón y Cajal Institute for Health Research (IRYCIS), CIBERESP, Ramón y Cajal University Hospital, Madrid, Spain

**Margaret C. Bash, M.D., M.P.H.** Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA  
Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

**John D. Baxter, M.D.** Division of Infectious Diseases, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, USA

**Gonzalo M.L. Bearman, M.D., M.P.H.** Chair, Division of Infectious Diseases, Epidemiology and Community Medicine, Richmond, VA, USA

Professor of Internal Medicine, Epidemiology and Community Medicine, Richmond, VA, USA

**Kirthana R. Beaulac, Pharm.D.** Tufts Medical Center, Boston, MA, USA

**Apostolos Beloukas, M.Sc., Ph.D.** Research Associate, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

**Thomas Benfield, M.D., D.M.Sci.** Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark

**Michael L. Bennish, M.D.** Executive Director, Mpilonhle, Mtubatuba, South Africa

**Michel G. Bergeron, O.Q., M.D., F.R.C.P.C.** Founder and Director, Centre de recherche en infectiologie, CHU de Quebec-Université Laval, CHUL, Québec City, QC, Canada

**Hiranmoy Bhattacharjee, Ph.D.** Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

**Giancarlo A. Biagini, Ph.D.** Research Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK

**John P. Bilello, Ph.D.** Principal Scientist, Infectious Diseases Biology-Discovery, Merck, West Point, PA, USA

**John S. Blanchard, Ph.D.** Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA

**Guy Boivin, M.D.** Professor of Microbiology, Canada Research Chair on Emerging Viruses and Antiviral Resistance Research Center in Infectious Diseases, Laval University, Quebec City, QC, Canada

**Robert A. Bonomo, M.D.** Professor of Medicine, Pharmacology, Molecular Biology and Microbiology, University Hospitals Case Medical Center, Cleveland, OH, USA

Chief, Medical Service, Louis Stokes Cleveland Department of Veteran Affairs Medical Center, University Hospitals Case Medical Center, Cleveland, OH, USA

Vice Chair for Veteran Affairs, Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA

**Michelle D. Brazas, Ph.D.** Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada

**Itzhak Brook, M.D., M.Sc.** Professor of Pediatrics, Georgetown University School of Medicine, Washington, DC, USA

**Robert W. Buckheit Jr., Ph.D.** ImQuest BioSciences, Inc., Frederick, MD, USA

**Joseph Adrian L. Buensalido, M.D.** Clinical Associate Professor, Section of Infectious Diseases, Department of Medicine, University of the Philippines—Philippine, General Hospital Manila, Metro Manila, Philippines

**Karen Bush, Ph.D.** Professor of Practice, Biotechnology Program, Biology Department, Indiana University, Bloomington, IN, USA

**Gerard Cangelosi, Ph.D.** Professor, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA

**Lilia López Cánovas, Ph.D.** Professor, Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, México City, Mexico

**Rafael Cantón, Ph.D.** Director, Department of Microbiology, Ramón y Cajal University Hospital, Madrid, Spain

Department of Microbiology, Faculty of Pharmacy Complutense, University Madrid, Madrid, Spain

**Jelena Catania, M.D.** Infectious Diseases Fellow, Duke University Medical Center, Durham, NC, USA

**Vincent Cattoir, Pharm.D., Ph.D.** Professor of Clinical Microbiology, Department of Clinical Microbiology, School of Medicine, Caen University Hospital, University of Caen Normandie, Caen, France

**Jaya Chakravarty, M.B.B.S., M.D.** Associate Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

**Jyotsna Chandra, Ph.D.** Senior Research Associate, Center for Medical Mycology, Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

**P.H. Chandrasekar, M.D.** Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Harper University Hospital, Detroit, MI, USA

**Kimberly C. Claeys, Pharm.D.** Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, USA

**Gerald C. Coles, M.A. Ph.D., Sc.D.** School of Veterinary Sciences, University of Bristol, Bristol, UK

**Lynn E. Connolly, M.D., Ph.D.** Achaogen, Inc., San Francisco, CA, USA  
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA, USA

**A.J. Cornell** School of Animal and Veterinary Sciences and Graham Centre for Agricultural Innovation, Charles Sturt University, Wagga Wagga, NSW, Australia

**Patrice M. Courvalin, M.D., F.R.C.P.** Unité des Agents Antibactériens, Institut Pasteur, Paris, France

**Mathieu Coutu** Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada

**Clyde S. Crumpacker II, M.D.** Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA  
Professor of Medicine, Harvard Medical School, Boston, MA, USA

**Sarah L. Cudmore, B.Sc.** Infection Prevention and Control, Public Health Ontario, Ottawa, ON, Canada

**Vanessa M. D'Costa, Ph.D.** Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada

**Florence Depardieu** Unité des Agents Antibactériens, Institut Pasteur, Paris, France

**Nainee Desai, Pharm.D.** Medical Affairs Department, Cubist Pharmaceuticals, Lexington, MA, USA

**Abhay Dhand, M.D.** Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA

**Carlos A. Diaz Granados, M.D., M.S.C.R.** Director of Clinical Sciences, Clinical Department, Sanofi Pasteur, Swiftwater, PA, USA

**Michael J. Doenhoff, B.Sc., Ph.D.** School of Life Sciences, University of Nottingham, University Park, Nottingham, UK

**Yohei Doi, M.D., Ph.D.** Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

**Robert A. Domaal, Ph.D.** Department of Pediatrics, Laboratory of Biochemical Pharmacology, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA, USA

**Summer Donovan, M.D.** Fellow, Division of Pediatric Infectious Diseases, Virginia Commonwealth University Medical Center, Richmond, VA, USA

**Shira I. Doron, M.D.** Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA

Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA

**Jacques Dumas, Ph.D.** Chief Scientific Officer, Tetrphase Pharmaceuticals, Watertown, MA, USA

**Herbert L. DuPont, M.D.** University of Texas School of Public Health, Houston, TX, USA  
McGovern Medical School, Baylor College of Physicians and Kelsey Research Foundation, Houston, TX, USA

**Noton K. Dutta, Ph.D.** Research Associate of Medicine, Division of Infectious Diseases, Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Maryam Ehteshami, Ph.D.** Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

**Matthew E. Falagas, M.D., M.Sc., D.Sc.** Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

Department of Medicine, Tufts University School of Medicine, Boston, MA, USA

**Loïc Favennec, M.D., Ph.D.** Professor of Pharmacy, Chief Medical Officer, Laboratory Parasitology-Mycolology, Hospital Charles Nicolle and EA 3800, University of Rouen, Rouen, France

**Lucía Fernández** Instituto de Productos Lacteos de Asturias (IPLA), Consejo Superior de Investigaciones Científicas (CSIC), Villaviciosa, Asturias, Spain

**Andrés Finzi, Ph.D.** Research Assistant Professor, Department of Microbiology, Infectiology and Immunology, Canada Research Chair on Retroviral Entry, Université de Montréal, Montreal, QC, Canada

**Gary E. Garber, M.D., F.R.C.P.C., F.A.C.P.** Infection Prevention and Control, Public Health Ontario, Ottawa, ON, Canada

**Consuelo Gómez García, Ph.D.** Professor, Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía (ENMyH), Instituto Politécnico Nacional, México City, Mexico

**Anna Maria Geretti, M.D., Ph.D., FRCPath.** Professor of Virology and Infectious Diseases, Honorary Consultant in Infectious Diseases, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

**Mahmoud A. Ghannoum, Ph.D.** Professor, Center for Medical Mycology, Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

**Vaidya Govindarajan** Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

**Fabrice E. Graf** Swiss Tropical and Public Health Institute, Parasite Chemotherapy Unit, Basel, Switzerland

**Robert M. Greenberg, Ph.D.** Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

**Ying-Shan Han, Ph.D.** McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

**Robert E.W. Hancock, Ph.D.** Canada Research Chair and Professor, Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada  
Director, Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada

**Kimberly E. Hanson, M.D., M.H.S.** Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA

**Bianca Heinrich, Ph.D.** Senior Scientist, Genomic Assays, Abcam, Inc., Cambridge, MA, USA

**David K. Henderson, M.D.** Office of the Deputy Director for Clinical Care, National Institutes of Health, Bethesda, MD, USA

**Brian D. Herman, Ph.D.** Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Veterans Affairs Medical Center, Atlanta, GA, USA

**Kathleen L. Horan, M.D.** Pulmonary Medicine, Virginia Mason Medical Center, Seattle, WA, USA

**Ann Huletsky, Ph.D.** Adjunct Professor, Centre de recherche en infectiologie, CHU de Quebec-Université Laval, CHUL, Québec City, QC, Canada

**Michael G. Ison, M.D., M.S.** Associate Professor, Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

**Michael R. Jacobs, M.D., Ph.D.** Professor of Pathology and Medicine, Director of Clinical Microbiology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH, USA

**George A. Jacoby, M.D.** Associate Professor of Medicine, Part-Time, Harvard Medical School, Boston, MA, USA

**Jisha John, M.D.** Fellow, Infectious Diseases, Wayne State University, Detroit, MI, USA

**Matthew D. Johnson** Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

**Glenn W. Kaatz, M.D.** Associate Chief of Staff, Research and Development, John D. Dingell VA Medical Center, Professor Medicine, Department of Internal Medicine and Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA

**Petros C. Karakousis, M.D.** Associate Professor of Medicine, Center for Tuberculosis Research, Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Angela D.M. Kashuba, B.Sc.Pharm., Pharm.D., D.A.B.C.P.** Professor and Chair, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina, Chapel Hill, NC, USA

**David E. Katz, M.D., M.P.H.** Director, Internal Medicine Department 'D', Shaare Zedek Medical Center, Hebrew University School of Medicine, Jerusalem, Israel

**Wasif A Khan, M.B.B.S., M.H.S.** Scientist, Infectious Disease Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

**Keith P. Klugman, M.D., Ph.D.** Director, Pneumonia, Bill and Melinda Gates Foundation, Seattle, WA, USA

**Joseph Kovacs, M.D.** Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

**Sebastian G. Kurz, M.D., Ph.D.** Division of Pulmonary and Critical Care, Department of Medicine, Tufts Medical Center, Boston, MA, USA

**Jannik-Helweg Larsen, M.D.** Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

**Roland Leclercq, M.D., Ph.D.** Professor of Clinical Microbiology, Department of Clinical Microbiology, Caen University Hospital, School of Medicine, University of Caen Normandie, Caen, France

**Danielle Légaré, Ph.D.** Centre de Recherche en Infectiologie du CHU de Québec, Université Laval, Quebec City, QC, Canada

**Donald P. Levine, M.D.** Professor of Medicine, Wayne State University, Detroit, MI, USA

**Shawn Lewenza, Ph.D.** Associate Professor, Faculty of Science and Technology, Athabasca University, Athabasca, AB, Canada

**Jennifer Li, B.Sc. (Hons)** Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

**Jian Li, Ph.D.** Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

**Xian-Zhi Li, M.D., Ph.D.** Team Leader, Human Safety Division, Veterinary Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada

**Stephen A. Locarnini, MBBS, BSc (Hon), PhD, FRCPath.** Head Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Australia

**Jose L. Lopez-Ribot, Pharm.D., Ph.D.** Department of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas at San Antonio, San Antonio, TX, USA

**R. Dwayne Lunsford, Ph.D.** Integrative Biology and Infectious Diseases Branch, Microbiology Program, NIDCR: National Institute of Dental and Craniofacial Research, Bethesda, MD, USA

**Joseph D. Lutgring, M.D.** Assistant Professor of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, USA

**Pauline Macheboeuf, Ph.D.** Senior Scientist, Institute for Structural Biology, CNRS, CEA, Université Grenoble Alpes, Grenoble, France

**Maria L. Magalhães** Department of Food and Animal Production State University of Santa Catarina, Lages, SC, Brazil

**Elias K. Manavathu, Ph.D.** Division of Infectious Diseases, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA

**Goutam Mandal, Ph.D.** Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

**Laurence A. Marchat, Ph.D.** Professor, Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía (ENMyH), Instituto Politécnico Nacional, México City, Mexico

**Pascal Mäser, Ph.D.** Swiss Tropical and Public Health Institute, Parasite Chemotherapy Unit, Basel, Switzerland

**Henry Masur, M.D.** Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA

**Kathryn A. Matthias, Ph.D.** Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA

**Douglas L. Mayers, M.D.** Chief Medical Officer, Treiber Therapeutics Cambridge, MA, USA

**Matthew McCarthy, M.D.** Transplantation-Oncology Infectious Diseases Program, Weill Cornell Center, New York, NY, USA

**Patrick F. McDermott, M.S., Ph.D.** Center for Veterinary Medicine, Office of Research, U. S. Food and Drug Administration, Laurel, MD, USA

**Lesley McGee, Ph.D.** Microbiologist, Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA

**John E. McGowan Jr. , M.D.** Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

**Joseph B. McPhee, Ph.D.** Assistant Professor, Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada

**Francis Mégraud, M.D.** National Reference Center for Campylobacters and Helicobacters, University Bordeaux Segalen, Bordeaux, France

**Thibault Mesplède, Ph.D.** McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

**Melissa B. Miller, Ph.D., D.(A.B.M.M.)** Department of Pathology and Lab Medicine, UNC School of Medicine, Chapel Hill, NC, USA

**Greg Moeck, Ph.D.** Vice President, Biology, The Medicines Company, Saint-Laurent, QC, Canada

**Stephen A. Morse, M.S.P.H., Ph.D.** Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging, Zoonotic and Infectious Diseases Centers for Disease Control and Prevention (Retired), Atlanta, GA, USA

**Rita Mukhopadhyay, Ph.D.** Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

**Alexandre Mzabi, M.D.** Laboratory Parasitology-Mycology, Hospital Maison Blanche and EA 3800, University of Reims Champagne-Ardenne, Reims, France

**Roger L. Nation, Ph.D.** Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

**Eleni Ntokou, Ph.D.** Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark

**Esther Orozco, Ph.D.** Professor, Departamento de Infectómica y Patogénesis Molecular, CINVESTAV, IPN, México City, Mexico

**Elizabeth M. O'Shaughnessy, M.D.** Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

**Marc Ouellette, Ph.D.** Professor Canada Research Chair in Antimicrobial Resistance, Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

**Tara N. Palmore, M.D.** Hospital Epidemiology Service, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

**Neil T. Parkin, Ph.D.** Executive Director, Data First Consulting, Inc., Belmont, CA, USA

**Sally R. Partridge, D.Phil.** Principal Research Fellow, Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital, Sydney, NSW, Australia

**David L. Paterson, M.D., Ph.D.** University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia

**Thomas F. Patterson, M.D., F.A.C.P., F.I.D.S.A.** Department of Medicine, Division of Infectious Diseases, University of Texas Health Science, Center at San Antonio and Audie Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA

**Federico Perez, M.D.** Medicine and Research Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

**D. Guillermo Pérez Ishiwara, Ph.D.** Professor, Centro de Investigación en Biotecnología Aplicada (CIBA), Instituto Politécnico Nacional, México City, Mexico

**John R. Perfect, M.D.** James B. Duke Professor of Medicine, Chief, Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA

**David S. Perlin, Ph.D.** Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA

**Jocelyne Piret, Ph.D.** Research Center in Infectious Diseases, CHU de Québec and Université, Laval, QC, Canada

**Bruno Pradines, Pharm.D., Ph.D.** Unité de Parasitologie et d'Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France

**Roger K. Prichard, Ph.D.** Institute of Parasitology, McGill University, St. Anne de Bellevue, QC, Canada

**Michael J. Pucci, Ph.D.** Executive Director, Spero Therapeutics, Cambridge, MA, USA

**Annette N. Ratcliff, Ph.D.** Technology Licensing Manager, Ohio State University, Columbus, OH, USA

**Jacqueline D. Reeves, Ph.D.** Director, Monogram Biosciences, Laboratory Corporation of America® Holdings, South San Francisco, CA, USA

**John H. Rex, M.D.** Senior Vice President and Chief Strategy Officer, AstraZeneca Infection Business Unit, Waltham, MA, USA

**Katherine Reyes, M.D., M.P.H.** Corporate Medical Director, Infection Prevention and Control, Henry Ford Health System, Detroit, MI, USA

Senior Staff Physician, Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA

**Louis B. Rice, M.D.** Brown University and Rhode Island Hospital, Providence, RI, USA



**Marilyn C. Roberts, Ph.D.** Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA

**Mario Alberto Rodríguez, Ph.D.** Professor, Departamento de Infectómica y Patogénesis Molecular, CINVESTAV, IPN, México City, Mexico

**Paul H. Roy, Ph.D.** Professor Emeritus, Centre de recherche en Infectiologie, Université Laval, Quebec City, QC, Canada

**William A. Rutala, Ph.D., M.P.H.** Department of Hospital Epidemiology, UNC Health Care System, Chapel Hill, NC, USA

Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA

**Michael J. Rybak, Pharm.D., M.P.H.** Director, Professor of Pharmacy and Adjunct Professor of Medicine, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA

**Max Salfinger, M.D.** Executive Director, Advanced Diagnostic Laboratories, Mycobacteriology and Pharmacokinetics, National Jewish Health, Denver, CO, USA

**Nicholas C. Sangster, B.Sc.(Vrt.), B.F.Sc., Ph.D.** School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia

**Celia A. Schiffer, Ph.D.** Professor and Director, Institute of Drug Resistance, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA

**Raymond F. Schinazi, Ph.D., D.Sc.** Frances Winship Walters Professor of Pediatrics, Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Veterans Affairs Medical Center, Atlanta, GA, USA

**Bryan D. Schindler, Ph.D.** Microbiologist II, NSF International, Ann Arbor, MI, USA

**Stefan Schwarz, Ph.D.** Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut (FLI), Neustadt-Mariensee, Germany

**Alisa W. Serio, Ph.D.** Achaogen, Inc., South San Francisco, CA, USA

**Mansi Sharma, Ph.D.** Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

**Ola E. Sköld, M.D., Ph.D.** Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

**Nicolas Sluis-Cremer, Ph.D.** Associate Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

**Jeffrey D. Smith, M.Sc.** Infection Prevention and Control, Public Health Ontario, Ottawa, ON, Canada

**Jordan R. Smith, Pharm.D.** Assistant Professor of Clinical Sciences, High Point University School of Pharmacy, High Point, NC, USA

**David R. Snyderman, M.D., F.A.C.P.** Professor of Medicine, Tufts University School of Medicine and Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA

**Jack D. Sobel, M.D.** Professor of Medicine, Dean, Wayne State University School of Medicine, Detroit Medical Center, Detroit, MI, USA

**Akos Somoskovi, M.D., Ph.D., D.Sc.** Department of Respiratory Medicine, Skaraborg Hospital, Skövde, Sweden

**Kathryn A. Stafford, B.Sc., M.Sc., Ph.D.** Research Assistant, Department of Clinical Veterinary Science, University of Bristol, Langford, Bristol, UK

**Judith N. Steenbergen, Ph.D.** Executive Director Clinical Microbiology, Cubist Pharmaceuticals, Lexington, MA, USA

**Shyam Sundar, M.D., F.R.C.P., F.N.A.** Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

**Göte Swedberg, Ph.D.** Associate Professor, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

**Vincent H. Tam, Pharm.D.** Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA

**Sandeep Tamber, Ph.D.** Research Scientist, Bureau of Microbial Hazards, Health Canada, Ottawa, ON, Canada

**Fred C. Tenover, Ph.D. D.(A.B.M.M.)** Vice President, Scientific Affairs, Cepheid, Sunnyvale, CA, USA

**Kyriakos K. Trigkidis, M.D.** Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

**Liza Valdivia, M.D.** Brown University and Rhode Island Hospital, Providence, RI, USA

**Jose A. Vazquez, M.D.** Chief, Division of Infectious Diseases, Professor of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA

**Colin M. Venner** Department of Microbiology and Immunology, Western University, London, ON, Canada

**Thierry Vernet, Ph.D.** Group Head, Institute for Structural Biology, CNRS, CEA, Université Grenoble Alpes, Grenoble, France

**Birte Vester, Ph.D.** Professor, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark

**Isabelle Villena, M.D.** Professor of Medicine, Chief Medical Officer, Laboratory Parasitology-Mycology, Hospital Maison Blanche and EA 3800, University of Reims Champagne-Ardenne, Reims, France

**Erhard Van der Vries, Ph.D.** Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany

**Mark A. Wainberg, Ph.D.** McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

**Thomas J. Walsh, M.D.** Department of Pediatrics and Transplantation-Oncology Infectious Diseases Program, Weill Cornell Center, New York, NY, USA

**Stephen A. Ward, Ph.D.** Research Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK

**David J. Weber, M.D., Ph.D.** Department of Hospital Epidemiology, UNC Health Care System, Chapel Hill, NC, USA

Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA

**Linda M. Weigel, Ph.D.** Principal Investigator, Biodefense Research and Development Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, USA

- L. Joseph Wheat, M.D.** Medical Director, MiraVista Diagnostics, Indianapolis, IN, USA
- Jean M. Whichard, D.V.M., Ph.D.** Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Nathan P. Wiederhold, Pharm.D.** Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
- Rob G. Woodgate, BSc, BVMS(Hons), PhD, GCLTHE** Senior Lecturer in Veterinary Parasitology, School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia
- Gerard D. Wright, Ph.D.** Professor of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada  
Director of Michael G. DeGroot Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada
- Hui-Ling Yen, Ph.D.** School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
- Nese Kurt Yilmaz, Ph.D.** Research Assistant Professor, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, USA
- Juwon Yim, Pharm.D.** Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, USA
- André Zapun, Ph.D.** Senior Scientist, Institute for Structural Biology, CNRS, CEA, Université Grenoble Alpes, Grenoble, France
- Evan J. Zasowski, Pharm.D., M.P.H.** Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, USA
- Marcus Zervos, M.D.** Division Head, Infectious Diseases, Henry Ford Health System, Detroit, MI, USA  
Professor of Medicine, Wayne State University School of Medicine, Detroit, MI, USA

**Gram Positive Bacterial Drug Resistance: Clinical**

Lesley McGee and Keith P. Klugman

## 1 Introduction

*Streptococcus pneumoniae* (the pneumococcus) has been an important human pathogen for over 100 years and continues to cause a wide variety of infections, ranging from mild otitis media and sinusitis to serious lower respiratory infections, as well as life-threatening invasive infections such as meningitis or pneumonia. Worldwide, morbidity and mortality due to pneumococcal infections are highest among young children below the age of 5 years, accounting for approximately one-third of the estimated 1.3 million deaths from pneumonia in 2011 [1]. The pneumococcus is a common colonizer in the respiratory tract, especially in the nasopharynx of children where it is often exposed to antimicrobials. As well as affecting the young, *S. pneumoniae* is an important cause of morbidity and mortality in the elderly; it is the most common etiological agent of community-acquired pneumonia, often resulting in hospitalization of previously healthy individuals.

Infections caused by *S. pneumoniae* were for many years traditionally treated with penicillin or ampicillin, to which this species was exquisitely sensitive when penicillin was first introduced in the 1940s. However, exposure to antimicrobials has led to the selection of resistant strains and clones, some of which have a global distribution; resistance, which was first seen in the 1960s, has continued to increase throughout the world in more recent decades. The emergence of resistance to penicillin and other beta-lactam antibiotics in pneumococci in the 1980s and 1990s led to the increased use of macrolides, fluoroquinolones (FQs), and other non-beta-lactam antibiotics for pneumococcal infections. Pharmacodynamics predicts that high doses of parenteral  $\beta$ -lactams with good Gram-positive

activity will currently treat most penicillin-resistant pneumococci. In contrast, oral  $\beta$ -lactams may fail, and high doses of amoxicillin are the best oral  $\beta$ -lactam drugs currently available to treat penicillin-resistant infections. Neither oral nor parenteral macrolides are able to treat macrolide-resistant pneumococcal infections. Fluoroquinolone resistance remains rare, but in patients previously exposed to these drugs, there is an increased risk of treatment failure due to selection of first-step mutants. Efforts to treat pneumococcal disease in both adults and children have been complicated by this increasing resistance to antimicrobials. The increase in antimicrobial resistance rates has been in part due to the selective pressures associated with the widespread use of antibiotics [2, 3] and the clonal expansion and spread of multiresistant pneumococcal clones [4]. More recently, the introduction of conjugate vaccine immunization of infants reduces the burden of resistance by eliminating vaccine types from invasive infections, but resistance continues to be selected in non-vaccine types. New classes of antimicrobials are needed to ensure long-term treatment options for pneumococcal infections.

This chapter will describe the emergence and incidence of antibiotic resistance in pneumococci, mechanisms, clinical implications, and impact of vaccines on resistance.

## 2 Epidemiology of the Pneumococcus and Risk Factors for Resistance

The incidence of pneumococcal disease remains the highest in children <2 years of age and in adults >65 years of age. Other important risk factors include underlying medical conditions such as chronic heart and lung disease, cigarette smoking, and immunodeficiency states such as asplenia, HIV, and sickle cell disease.

*S. pneumoniae* colonizes the upper respiratory tract and is part of the normal flora of healthy individuals. Pneumococcal colonization is a dynamic process. A particular serotype can be carried for many months before being eradicated or replaced by a different serotype. Carriage increases in the

---

L. McGee, Ph.D. (✉)  
Microbiologist, Respiratory Diseases Branch, Centers for Disease  
Control and Prevention, Atlanta, GA, USA  
e-mail: [lmcgee@cdc.gov](mailto:lmcgee@cdc.gov)

K.P. Klugman, M.D., Ph.D.  
Pneumonia, Bill and Melinda Gates Foundation, Seattle, WA, USA

first few months of life, and universally, carriage rates are highest in young children (40–60%), compared with older children (12%), adolescents (6–10%), and adults (3–4%) [5, 6]. Factors associated with increased carriage include winter season, situations of overcrowding such as day-care attendance, and living in crowded conditions [7]. Prior antibiotic use does not appear to alter the rate of carriage but does promote carriage with antibiotic-resistant strains, particularly to  $\beta$ -lactam antibiotics [8].

Investigations of serotype prevalence from various parts of the world have shown that serotype distribution varies with geographical location and age [9]. The distribution of serotypes also varies between carriage isolates and invasive disease, and antibiotic resistance (at least in the pre-conjugate vaccine era) is most frequent in pneumococcal serotypes that are carried by children (types/groups 6, 9, 14, 19, and 23) [9]. The probable reason is the frequent use of antibiotic therapy in small children and hence exposure of strains of these serotypes to antimicrobial drugs, providing a selective advantage to resistant mutants [10].

There are multiple risk factors for acquisition of infection with antibiotic-resistant pneumococci. Most of these factors have a commonality in exposure to the drugs that select the resistance. This exposure to  $\beta$ -lactams can be at the level of a country [11, 12], province [13], day care [14], family [15], or individual [16]. Macrolide resistance is also a function of exposure, particularly of long-acting drugs such as azithromycin [17]. The selection of resistant strains is complicated by multiple resistances where macrolides appear to be better selectors of multiresistant strains than do  $\beta$ -lactam drugs [16]. Antimicrobial resistance may be seasonal, with higher rates detected during increased antibiotic use in the winter months [18]. The issue of cross-resistance extends to treatment of such diverse organisms as the malaria parasite, where treatment with Fansidar selects trimethoprim-sulfamethoxazole resistance in pneumococci [19].

Most resistance is selected as mentioned above in children, but the exception is fluoroquinolone resistance which is selected in adults [20–22] as these agents are not usually given to children. In the unusual circumstance of fluoroquinolone treatment of children, for example, as treatment of drug-resistant tuberculosis, the selection of fluoroquinolone-resistant pneumococci occurs, and these strains are associated with invasive disease [23].

Children in rural settings generally have less access to antibiotics and therefore have less resistant strains [24, 25], while in some large cities, where poorer children live in the city center with less access to care and more affluent children live in the suburbs, there may be more resistance outside the city [26].

Little is known about the impact of drug dose on the selection of resistant strains, but there is a prospective study that suggests that high dose and short duration of amoxicillin

therapy may select less resistance than the same total dose given over a longer period of time [27].

Nosocomial acquisition is a major risk for resistant pneumococci [28], and the first multiply resistant strains were selected in hospital [29]. Recent hospitalization is also a risk for infection with multiply resistant pneumococci [25].

HIV infection is a risk for increased resistance in pneumococcal infections due to the frequent exposure of these patients to antibiotic prophylaxis with trimethoprim-sulfamethoxazole [30], as well as the fact that these patients, especially HIV-infected women, are at risk due to the antibiotic-resistant serotypes carried by children [31].

Children exposed to conjugate vaccine, as well as adults living in countries where these vaccines are routinely administered to children, are at lower risk for pneumococcal infections due to resistant strains as described in Sect. 10.

---

### 3 The Role of Clones in Resistance

The increase in antibiotic resistance and the introduction of conjugate vaccines have focused attention on the epidemiology of *S. pneumoniae*. Molecular typing data from numerous studies over the past few decades has added to our knowledge by showing that although there is considerable diversity among resistant strains within most serotypes, a small number of highly successful clones have emerged within countries and in some cases have achieved massive geographical spread [4]. In response to this, the Pneumococcal Molecular Epidemiology Network (PMEN) was established in 1997 with the aim of standardizing nomenclature and classification of pneumococcal clones worldwide. At present, PMEN has documented 43 international clones, 26 of which are multidrug-resistant. The best characterized, and most widely spread of these international clones, is the Spain<sup>23F</sup>-1 or PMEN1 originally described in Spain during the 1980s. Intercontinental spread of this clone to the USA was described in 1991 and shortly thereafter in the UK, South Africa, Hungary, and South America [32]. By the late 1990s, it was estimated that approximately 40% of penicillin non-susceptible pneumococci circulating in the USA were members of this clone [33], and while strains belonging to this genotype continue to be isolated today in many countries all over the world, their prevalence has decreased in countries where conjugate vaccines have been introduced [34, 35]. Recent studies [32, 36, 37] looking at whole genome sequencing of pneumococci representing PMEN1 show that there is a considerable amount of genetic diversity within this lineage. This diversity, which largely results from hundreds of recombination events, indicates rapid genomic evolution and presumably allowed rapid response to selective pressures such as those imposed by vaccine and antibiotic use [36].

Clonal analyses of large surveillance collections of pneumococci have revealed the remarkable dominance of a small number of clones among the antimicrobial-resistant population. As these global clones have spread, they have been exposed to new selective pressures applied by regional variations in the use of different antibiotics. This has led to the further selection of strains belonging to these clones with varying antimicrobial resistance patterns. These resistant clones have also been exposed more recently to conjugate vaccines, and shifts in both serotype and clonal types have been documented [34, 35, 38]. For example, in the USA serotype 19A strains have been identified as the main cause of serotype replacement in both carriage and invasive disease post-PCV7 introduction; this has coincided with a significant increase in penicillin resistance and multidrug resistance among 19A clinical strains [34, 35, 39]. The majority of penicillin-resistant 19A strains belonged to emerging clonal complex 320 (CC320), which is descended from multidrug-resistant Taiwan<sup>19F</sup>-14 (PMEN14). In 1999, prior to PCV7 introduction, only CC199 and three minor clones were apparent among 19A strains. In 2005 post-PCV, 11 clonal complexes were detected, including ST695 capsular variants of serotype 4 [38, 40].

#### 4 Laboratory Detection of Resistance

Even though we can now identify pneumococci and many resistances based upon genetic features, bacterial culture and phenotypic susceptibility tests remain the gold standard approaches in clinical laboratories. Because it is a fastidious organism, however, specific methods and interpretative criteria developed by a variety of professional bodies such as the Clinical and Laboratory Standards Institute (CLSI, formerly the National Committee for Clinical Laboratory Standards, NCCLS), the British Society for Antimicrobial Chemotherapy (BSAC), and the European Committee on Antimicrobial Susceptibility testing (EUCAST) must be used to ensure accurate and consistent susceptibility results [41]. Because the breakpoints are determined on the basis of microbiological, pharmacological, and clinical outcome data and since patterns of resistance to antimicrobial drugs continue to evolve, changes to breakpoints can occur during the lifetime of an antibiotic. A good example is the CLSI revised breakpoints for penicillin adopted in January 2008 to redefine the susceptibility of meningeal and non-meningeal pneumococcal isolates [42].

Culture of clinical specimens and antibiotic susceptibility testing are often slow, taking up to 48 h, and are often negative due to prior antibiotic use before sampling or autolysis of the organism. Rapid tests, based mainly on immunological or molecular techniques, have gained importance for the detection of bacteria and antibacterial resistance over the last

two decades. PCR has been shown to be a useful tool for the rapid identification of *S. pneumoniae* from both clinical specimens and bacterial isolates [43, 44]. The increased use of molecular tests such as PCR for the diagnosis of bacterial infections has led in turn to an increased demand for antibiotic susceptibility testing using molecular methods. However, unlike phenotypic testing for antibiotic susceptibility, which examines all resistance mechanisms for a particular antibiotic simultaneously, molecular testing can detect only known resistance mechanisms. A variety of assays has been described to detect the presence of specific resistance genes in pneumococcal isolates and also directly from clinical specimens [44–50]. The majority of these assays are PCR based [44–47], although sequencing approaches and microarrays have also been used [49, 50].

#### 5 Resistance to $\beta$ -Lactams

With the advent of penicillin G therapy in the 1940s, the case fatality rate for pneumonia fell dramatically [51]. Pneumococcal isolates were initially extremely sensitive to the drug with MICs of  $\leq 0.01$  mg/L. Penicillin resistance was demonstrated in laboratory mutants soon after the introduction of penicillin G into clinical use but was not reported in clinical strains until 20 years later when investigators in Boston reported penicillin resistance in 2 of 200 strains [52]. Initially, the observation was not considered relevant, until a report by Hansman and Bullen [53] describing a penicillin-resistant strain (MIC 0.6 mg/L) isolated in Australia from the sputum of a patient with hypogammaglobulinemia. Subsequently, resistant strains were identified in New Guinea and Australia, and in 1974, the first clinical infection due to a penicillin non-susceptible strain was reported in the USA [54, 55]. In 1977, pneumococci resistant to penicillin began to appear in South Africa, and in 1978, the first multidrug-resistant pneumococci were documented in Johannesburg, South Africa [29, 56]. In between and after these initial reports, detection of penicillin-resistant pneumococci among clinical isolates began to be reported with increasing frequency in the clinical and microbiological setting. Today, penicillin-resistant strains are encountered in all countries in which adequate surveys are conducted. Recombination appears to be an essential mechanism in the evolution of beta-lactam resistance in nature, and resultant clonal spread of resistant strains plays an enormous role in the increase in beta-lactam resistance globally [4].

$\beta$ -lactam antibiotics inhibit the growth of pneumococci by inactivation of cell wall synthesizing penicillin-binding proteins (PBPs).  $\beta$ -lactam resistance in pneumococci occurs by alterations in the key cell wall PBPs and the creation of *pbp* genes with decreased affinities for these antimicrobials. Six PBPs have been identified in *S. pneumoniae* (PBPs 1a, 1b,

2a, 2b, 2x, 3), of which PBP2X and PBP2B have been confirmed to be essential for cell growth [57, 58]. Resistance to  $\beta$ -lactams is complex and involves a multifactorial process. Depending on the selecting  $\beta$ -lactam, different combinations of *pbp* genes and mutations within these *pbp* genes are involved in conferring resistance. Little data exist for the role of PBPs 1b, 2a, and 3 [59, 60] as resistance determinants, and altered PBPs 2x, 2b, and 1a are the major players in the development of  $\beta$ -lactam resistance in most clinical isolates. The altered PBPs are encoded by genes with a mosaic structure and can undergo inter- and intraspecies recombination so that parts of the genes are replaced by allelic variants that differ by up to 20% in DNA sequence [61]. Mosaic sequences of *pbp* genes are very difficult to classify and organize. In general, the resistance profile of particular isolates results from interactions between various combinations of altered PBPs, in conjunction with a functional *murMN* operon which encodes enzymes involved in the synthesis of branched structured mucopeptides. Several other genes have been implicated in  $\beta$ -lactam resistance in selected clinical isolates that contribute to resistance in addition to mutations in PBP genes [61], although certain combinations of these three altered PBP genes alone appear to confer resistance.

Resistance to penicillin is associated with some degree of non-susceptibility to all  $\beta$ -lactam antibiotics. Mutations in PBP2x confer low-grade penicillin resistance and may be sufficient for the cell to become non-susceptible to oral cephalosporins. Alterations in PBP2b result in even higher MICs to penicillin [62], while changes in PBP1a are required for high-level penicillin resistance [60, 63] and extended-spectrum cephalosporin resistance [64, 65]. Isolates with very high levels of penicillin resistance (MICs  $\geq 8$  mg/L) require changes in all three PBPs (i.e., 1a, 2b, and 2x) and sometimes in additional non-PBP resistance determinants such as MurM [66].

Resistance rates reported for amoxicillin are relatively low (<5%) as a result of the favorable pharmacodynamic properties of this agent [67, 68]. Generally, MICs to amoxicillin are equal to or two to four times less than the MIC of penicillin [69]. In the past, there have been numerous reports of strains with amoxicillin MICs (4–16 mg/L) higher than penicillin MICs (2–8 mg/L) [68, 70–72]. In particular, PBP2b appears to play a significant role in mediating the expression of this resistance phenotype [73]. In addition to typical changes in PBP1a and PBP2x, these strains have unique mutations in the 590–641 region of the PBP2b gene in close proximity to the active binding site [68, 72, 73].

Resistance to cephalosporins may develop with mutations in the *pbp1a* and *pbp2x* genes, and the close linkage of these two genes on the chromosome is conducive to the transfer of both genes in a single transformation step [64, 74]. PBP2b is not a target for cephalosporins so would remain unaltered in isolates expressing cephalosporin resistance and susceptibil-

ity to penicillin [75]. Most, but not all, extended-spectrum cephalosporin-resistant strains are also penicillin-resistant, and as with amoxicillin, the MICs of cefotaxime and ceftriaxone are usually lower than the MICs of penicillin. Newer antibiotics such as ceftaroline and ceftobiprole appear to be more active and have greater affinity for altered *pbp* genes allowing it to be active against strains with elevated MICs to other  $\beta$ -lactams [76, 77]. In the early 1990s in the USA, pneumococci with high-level cefotaxime and ceftriaxone (2–32 mg/L) resistance were detected [78], and this high-level resistance was due to alterations in PBPs 1A and 2X [65]. The cephalosporin MICs were in excess of the MICs of penicillin for these isolates, and specific point mutations (Thr<sub>550</sub>Ala) in the *pbp2x* gene were associated with this phenotype [65]. These cephalosporin-resistant strains emerged within a few preexisting clones and demonstrate that point mutations as well as recombinational events are important in the development of resistance to  $\beta$ -lactam antibiotics in pneumococci.

---

## 6 Resistance to Macrolides

The macrolides have been used extensively to treat community-acquired respiratory tract infections worldwide, and in recent years, resistance to macrolide antibiotics (e.g., erythromycin, clarithromycin, and azithromycin) in *S. pneumoniae* has escalated dramatically. Macrolide-resistant *S. pneumoniae* are now more common than penicillin-resistant *S. pneumoniae* in many parts of the world [79]. However, both macrolide resistance rates and resistance mechanisms may vary considerably depending on location [80]. Erythromycin resistance rates range from about 15% in Latin America to as high as 80% recorded among isolates in Far East [81], and these differences probably reflect, in part, the variation in antibiotic prescribing behavior between different countries.

Macrolide resistance in *S. pneumoniae* is mediated primarily by two mechanisms: target modification and active efflux. The most common form of target modification is usually the result of dimethylation of the adenine residue at position 2058 on the 23S rRNA by a methylase enzyme [82]. This mechanism confers constitutive high-level resistance (MIC, >256 mg/L) to 14-, 15-, and 16-member macrolides, lincosamides, and streptogramins B, the so-called MLS<sub>B</sub> phenotype. In *S. pneumoniae*, methylation is *erm*(B) mediated in almost all cases, although, more rarely, a methylase encoded by *erm*(A) subclass *erm*(TR) has been implicated [83]. Target modification by point mutations in domain II and V of 23S rRNA and in the genes encoding riboproteins L4 and L22 can also confer macrolide resistance and has been documented in clinical isolates from widely distributed global sites [84–86].



In certain countries, such as the USA [87], active efflux is the major mechanism for macrolide resistance. It confers low-level resistance (MIC, 1–16 mg/L) to 14- and 15-member macrolides but not to 16-member macrolides, lincosamides, and streptogramin B and is phenotypically referred to as the M phenotype. Active efflux is encoded by *mef*-class genes, which include several variants, the abundant *mef*(A) and *mef*(E), which share 90% sequence identity, and the rare variant *mef*(I) which has only been described in two Italian clinical strains [88].

In pneumococci the three subclasses of *mef* are carried on a number of similar but distinct genetic elements. *mef*(A) is located on the defective transposon Tn1207.1 or the closely related Tn1207.3 [89], whereas *mef*(E) is typically carried on the mega (macrolide efflux genetic assembly) element [90]. The *mef*(I) gene exhibits 91.4 and 93.6% homologies to the *mef*(A) gene of Tn1207.1 and the *mef*(E) gene of the mega element, respectively [88], and is carried on a nonmobile composite structure, designated 5216IQ complex [91].

Worldwide *erm*(B) and *mef*(A or E) mechanisms account for the majority of macrolide resistance among pneumococci, and the prevalence of these genes varies considerably among countries. In recent years, the presence of both the *erm*(B) and the *mef* genes in *S. pneumoniae* clinical isolates has been increasingly recognized, particularly in Asian countries but also in Europe, S. Africa, and the USA [92, 93]. The PROTEKT study reported a 12% global prevalence of macrolide-resistant isolates positive for both *erm*(B) and *mef*(A) in 2003–2004 [81].

The majority of dual-positive isolates exhibit multidrug resistance and are clonal lineages of Taiwan<sup>19F</sup>-14, mostly multilocus sequence type 320, 271, and 236 [4, 92–94]. It appears that the global increase in macrolide-resistant strains carrying both the *erm*(B) and *mef* genes is being driven in part by the diversification and expansion of this Taiwan<sup>19F</sup>-14 clone following conjugate vaccine introduction. This was especially true of the major 19A ST320 variant in the USA, which became the single most common IPD causing genetic complex in the USA prior to PCV13 implementation.

## 7 Resistance to Fluoroquinolones

Due to the increased rates of resistance to  $\beta$ -lactam and macrolide antibiotics among pneumococcal strains, fluoroquinolones (FQs) are now included among the choices for first-line therapy in clinical guidelines for the treatment of respiratory tract infections and pneumonia. A direct correlation between the use of FQs and the prevalence of resistance in *S. pneumoniae* has been described [95–97]; however, despite the increased use of FQs, the resistance of *S. pneumoniae* to the newer members of the family is uncommonly found. Reports from Europe, the USA, and Canada showed levels of resis-

tance to levofloxacin and moxifloxacin below 2% [95–97]. Three major events may have contributed to this low level of resistance: the replacement of the old FQ ciprofloxacin by the more active levofloxacin and moxifloxacin, the introduction of the pneumococcal conjugate vaccine, and, probably, the fact that children who are the main reservoir of pneumococci are not generally treated with FQs. This is supported by a recent study from South Africa showing a rise in FQ resistance in pneumococci isolated from children treated with FQ due to MDR tuberculosis [98]. In countries that report increasing incidence of resistance, the proportion of resistant isolates is much higher among older subjects and patients with chronic lung disease, a patient population that is frequently exposed to FQ [99].

Two mechanisms that decrease susceptibility to FQs in pneumococci have been identified: target alteration and reduced accumulation due to efflux. Resistance associated with target modification requires a combination of mutations in the quinolone resistance-determining region (QRDR) of the genes encoding the DNA gyrase and DNA topoisomerase IV subunits. First-step mutants generally result from spontaneous mutations in the preferential target for a given FQ, ParC for ciprofloxacin, and levofloxacin or GyrA for moxifloxacin, gatifloxacin, and gemifloxacin [100, 101]. Some isolates with a first-step mutation in *parC* gene have ciprofloxacin MICs that would indicate they are clinically susceptible (MIC, <4 mg/L) and these strains would not be identified using routine antibiotic susceptibility testing [102]. The population of isolates with first-step mutations is important because, compared with strains without these first-step mutations, they are more likely to develop high-level resistance during therapy with the acquisition of a second-step mutation [103, 104]. In the second-step mutants, amino acid substitutions are present in both topoisomerase IV and gyrase, most frequently affecting ParC and GyrA and less so ParE and GyrB [105].

Several mutations have been described in these enzymes, but only a few have been shown by in vitro studies to confer resistance: S81F or Y, C, or I and E85K in *gyrA*; E474K in *gyrB*; A63T, S79F, or Y or L and D83G or N in *parC*; and E474K and D435N or H in *parE* [100, 106]. Other frequently described mutations are K137N in *parC* and I460V in *parE*, which appear to not contribute to FQ resistance because they are commonly found in susceptible strains, and no evidence exists for their conferring FQ resistance in vitro [107]. A Q118K in *gyrA* together with S79F in *parC* in a FQ-resistant isolate resulted in treatment failure [108].

Another mechanism underlying non-susceptibility to FQs in some pneumococcal isolates is an increase in active efflux which affects quinolones such as ciprofloxacin [109]. In contrast to the *mefA* gene conferring macrolide resistance, the efflux mechanisms in FQ resistance are poorly characterized and have primarily been demonstrated in isolates with low-level quinolone resistance [101]. They are not encoded by

resistance genes but are thought to be overexpressed in 8–45 % of pneumococcal strains [110]. Little is known about the mechanism of the expression regulation of PmrA, but the efflux pump can be blocked by the plant alkaloid reserpine and, to a lesser degree, by verapamil [111]. Efflux may not confer complete resistance but may be able to lower intracellular FQ to sublethal concentrations, fostering the occurrence of QRDR mutations [112].

In contrast to  $\beta$ -lactam resistance, horizontal gene transfer and the role recombination plays in the evolution of FQ resistance are uncertain. Both intra- and interspecies transfers of FQ resistance loci have been found to occur in vivo, but the frequency of such events appears to be rare. In vitro models report a higher frequency for recombination of QRDRs between viridans group streptococci and *S. pneumoniae* compared to that of spontaneous mutations [113]; however, this level of recombination does not appear to be replicated in vivo [114]. Published studies addressing this question of recombination found evidence for horizontal gene transfer in 0–11 % of FQ-resistant isolates, and interestingly, this ratio seems to be higher in respiratory isolates than in invasive isolates [115–118].

Fluoroquinolone resistance has been reported in a number of international pneumococcal clones that have been associated with the evolution of resistance to penicillin and macrolides [119, 120]. However, the role that clonal spread plays in the increase of FQ resistance is controversial, with studies placing different significance on its importance. The increased prevalence of levofloxacin resistance that was reported from Hong Kong between 1995 and 2001 was suggested to be associated with the dissemination of strains related to the Spain<sup>23F</sup>-1 clone. However, several studies have shown that clonal spread does not play a significant role in the increase of FQ resistance [120–122]. Data on levofloxacin-resistant pneumococci from 25 countries analyzed as part of the PROTEKT study (1999–2000) showed the majority were genetically unrelated, although 34 % belonged to the Spain<sup>23F</sup>-1 clone [120]. These studies suggest that both clonal dissemination and the emergence of newly resistant strains contribute to the spread of FQ resistance.

## 8 Resistance to Newer Classes of Antibiotics

Telithromycin was the first ketolide drug approved for clinical use; however, safety issues have limited the clinical utility of this drug [123]. Both cethromycin (ABT-773) and solithromycin (CEM-101), a novel fluoroketolide, have shown improved activity against macrolide-resistant as well as telithromycin-intermediate and telithromycin-resistant organisms [124–126]. This enhanced potency shows promise for future clinical use for these compounds, subject to

pharmacokinetic/pharmacodynamic, toxicity, and animal infection model studies. High-level telithromycin resistance in *S. pneumoniae* has been experimentally generated by mutations in domain II or V of 23S rRNA gene and ribosomal proteins L4 and L22 [127] and is easily created from a macrolide-resistant strain by the deletion or mutation of the region upstream of *erm(B)* [128]. In contrast, clinical telithromycin resistance in *S. pneumoniae* remains rare. Farrell reported that among a worldwide collection of 13 874 *S. pneumoniae* isolates, isolated between 1999 and 2003, only ten were resistant, with MICs  $\geq 4$  mg/L and all contained *erm(B)* gene [129]. Mutations in 23S rRNA, L4, and L22 have also been found in clinical telithromycin-resistant isolates [130, 131], and a combination of mutated genes can result in a higher telithromycin resistance than mutation of only one gene [132, 133]. Wolter and colleagues demonstrated that *erm(B)* with a deletion in the leader sequence was responsible for high-level telithromycin resistance in a strain isolated in Canada in 2007 [134].

Linezolid is the first in the class oxazolidinone that was approved for clinical use in 2000 for the treatment of nosocomial and community-acquired pneumonia. Linezolid binds to the 50S subunit of the bacterial ribosome via interactions with the central loop segment of domain V of the 23S rRNA to block the formation of protein synthesis initiation complexes. To date, linezolid non-susceptible pneumococcal strains are extremely rare [129, 135]. Recent data from the US LEADER and global ZAAPS surveillance systems show no linezolid non-susceptible isolates among 2150 *S. pneumoniae* isolates tested in 2011 [136, 137]. Reports of non-susceptibility to linezolid have been sporadic among clinical isolates of staphylococci and enterococci, and resistance has been found to be conferred by mutations in domain V of 23S rRNA [138]. In pneumococci, Wolter et al. [139] have described two clinical isolates with decreased susceptibility to linezolid (MICs 4 mg/L) which were found to contain 6-bp deletions in the gene encoding the riboprotein L4. The L4 deletions were also found to confer a novel mechanism of simultaneous resistance to macrolides, oxazolidinones, and chloramphenicol. A more recent study identified two additional linezolid non-susceptible pneumococci from the USA within the Centers for Disease Control and Prevention (CDC) Active Bacterial Core Surveillance (ABCs) program with mutations and deletions within the *rplD* gene [140]. Whole genome sequencing of linezolid-resistant laboratory-generated mutants has also revealed a role in resistance for a 23S rRNA methyltransferase (*spr0333*) and for the ABC proteins PatA and PatB [141]. A proteomic and transcriptomic screen suggested increased energy requirement needs associated with the burden of resistance in these laboratory-derived mutants [142]. Second-generation oxazolidinones like tedizolid, which is a protein synthesis inhibitor, are in clinical development for the treatment of

Gram-positive infections. Tedizolid has demonstrated potent in vitro activity against penicillin-resistant *S. pneumoniae*, including linezolid-resistant strains [143].

Resistance to quinupristin-dalfopristin among Gram-positive cocci has been very uncommon. Two clinical isolates among 8837 (0.02%) *Streptococcus pneumoniae* isolates were discovered in 2001–2002 with MICs of 4 mg/L. Each had a 5-amino acid tandem duplication (RTAHI) in the L22 ribosomal protein gene (rplV) preventing synergistic ribosomal binding of the streptogramin combination [144].

---

## 9 Resistance to Other Agents

One class of antimicrobial agents previously used often in clinical practice is the tetracyclines, which are broad-spectrum bacteriostatic drugs shown to be active against pneumococci. Reflecting patterns of past usage, in some countries reported rates of non-susceptibility to tetracyclines remain the most frequently observed resistance phenotype [145]. In *S. pneumoniae* tetracycline resistance is due to the protection of the bacterial 30S ribosome subunit against antibiotic binding by the TetM or TetO [146, 147] proteins, with the *tet(M)* gene being far more common than the *tet(O)* gene in pneumococci. In streptococci, *tet(M)* is usually associated with highly mobile conjugative transposons of the *Tn916–Tn1545* type and large composite structures like *Tn5253* and *Tn3872*. A recent study discovered the oldest known examples of two different *Tn916*-like, *tet(M)*-containing elements identified among pneumococci dated from 1967 and 1968 [145]. These transposons often carry other resistance genes, such as *erm(B)* coding for resistance to macrolides, lincosamides, and streptogramins B which explains the persistence of tetracycline resistance (these transposons continue to be selected by macrolides). The comparison of *tet(M)* sequences in multidrug-resistant isolates reveals a high degree of allelic variation [148]. There is evidence of clonal distribution of selected alleles as well as horizontal movement of the mobile elements carrying *tet(M)* [149, 150].

The use of rifampin combined with either  $\beta$ -lactam antibiotics or vancomycin has been recommended for the treatment of meningitis caused by multiresistant pneumococci. Rifampin has been used in combined therapy to treat tuberculosis and resistant staphylococci, and it is extensively used in the prophylaxis of *Neisseria meningitidis* and *Haemophilus influenzae* type b exposure. The prevalence of rifampin resistance among pneumococcal isolates is low at present, and reported rates vary between 0.1% and 1.5% [151, 152]. Rifampin resistance has been described in several bacterial species and is caused by an alteration of the  $\beta$ -subunit of RNA polymerase, the target for the antibiotic. Resistance to rifampin in pneumococci has been linked to mutations in clusters N, I, II, and III of the *rpoB* gene, which encodes the  $\beta$ -subunit [153, 154].

Resistance to chloramphenicol in *S. pneumoniae* is due to the acetylation of the antibiotic by the production of a chloramphenicol acetyltransferase (CAT). The *cat* gene in pneumococcal isolates is carried on the conjugative transposon *Tn5253*, a composite transposon consisting of the tetracycline resistance transposon, *Tn5251*, and *Tn5252* which carries the chloramphenicol resistance determinant [155]. Chloramphenicol-resistant strains have been shown to contain sequences homologous to *cat*<sub>pC194</sub> and other flanking sequences from *S. aureus* plasmid pC194 [156].

Trimethoprim and sulfamethoxazole are used extensively in combination as the drug co-trimoxazole. Co-trimoxazole has been used in the treatment of a range of *S. pneumoniae* diseases, especially in children, because it is inexpensive and generally effective. Resistance to co-trimoxazole has increased dramatically in many regions of the world, and recent surveillance studies show rates ranging from 19% in Europe to around 50% associated with HIV infection in Africa and >60% in Asia [29, 157, 158]. Resistance to co-trimoxazole is often associated with resistance to other antibiotics, especially to penicillin. Trimethoprim resistance in pneumococci has been reported to result from a single amino acid substitution (Ile-100  $\rightarrow$  Leu) in the dihydrofolate reductase (DHFR) protein [159] and often associated with mosaic alleles. Additional mutations have also been reported which seem to enhance resistance and modulate the effects of existing alterations on the affinity of DHFR for its natural substrates [160]. In many cases, resistance to sulfonamides is associated with chromosomal mutations within the gene encoding dihydropteroate synthase (DHPS). Different studies have reported the occurrence of single and/or multiple amino acid mutations in the DHPS of sulfonamide-resistant clinical isolates of *S. pneumoniae* [161–163]. The use of Fansidar therapy for malaria in Africa has been shown to increase co-trimoxazole resistance in pneumococci [19].

---

## 10 Clinical Relevance of Antibiotic Resistance

When penicillin-resistant pneumococci were first isolated from adults, there was an implicit assumption that such strains would fail intravenous penicillin therapy [164, 165]. As our appreciation of pharmacodynamics has allowed the understanding of the time-based mode of action of  $\beta$ -lactams, it is clear that the very high levels of penicillin achieved by intravenous therapy exceed the MICs of strains up to 8 mg/L for most of the short 4–6 h dosing interval for high-dose intravenous penicillin [166]. Such highly penicillin-resistant strains remain rare, and there is little evidence for the failure of intravenous penicillin, amoxicillin, cefotaxime, or ceftriaxone [167, 168] due to penicillin resistance. It is possible that less active intravenous agents such as cefuroxime [169]

may fail to treat penicillin-resistant infections, and  $\beta$ -lactams with a more Gram-negative spectrum such as ticarcillin [164] and ceftazidime [170] should not be used to treat penicillin-resistant pneumococcal infections. It is likely that oral  $\beta$ -lactam therapy may fail in the management of pneumococcal infections such as otitis media when the strains become intermediately ( $\text{MIC} \geq 0.1$  mg/L) resistant to penicillin. Poorly active cephalosporins such as cefaclor fail more often than cefuroxime [171, 172], and high-dose amoxicillin is the most active oral agent available against penicillin-resistant pneumococcal otitis media [173]. It is likely that the inferences made for otitis will be similar for sinusitis [174].  $\beta$ -lactam resistance is clinically important for meningitis treatment where penicillin has been shown to fail [175, 176] even for intermediately resistant strains because of the poor penetration of penicillin through the blood-brain barrier. Extended spectrum cephalosporins fail too when there is full penicillin resistance in meningitis ( $\text{MIC} \geq 2$  mg/L; associated with cefotaxime or ceftriaxone  $\text{MIC}'s \geq 1$  mg/L) [177, 178]. The empiric therapy therefore of penicillin-resistant pneumococcal meningitis is cefotaxime plus vancomycin or ceftriaxone plus vancomycin, based on the observation that these drugs in combination are able to eradicate cephalosporin-resistant pneumococci from the CSF better [178] than either drug alone [179, 180].

Macrolide resistance is associated in most instances with  $\text{MICs} > 2$  mg/L regardless of the mechanism of macrolide resistance, and treatment of these strains with macrolides has been shown to fail [181, 182], both in the management of otitis media [171, 172] and of pneumonia [183]. These failures are in keeping with our knowledge of the pharmacodynamics of these agents [184].

Trimethoprim-sulfamethoxazole has been shown to not be able to eradicate from the middle ear, strains resistant to that agent [185].

Fluoroquinolones fail to successfully treat pneumococcal infections when preexisting resistant strains are present or even when first-step mutations in the *parC* gene are present [186]. Immunocompromised patients may be most at risk for repeated infections due to fluoroquinolones-resistant strains [187].

## 11 Impact of Conjugate Vaccine

The introduction of conjugate pneumococcal vaccine has not only reduced the burden of invasive disease in children [188] but has impacted on carriage and thus on the burden of disease in adults by preventing the spread of vaccine-type resistant strains to adults [189]. Direct demonstration of the impact of conjugate vaccine on antibiotic-resistant invasive disease was demonstrated in the 9-valent conjugate vaccine trial in South Africa [190], while multistate studies [191] have demonstrated a significant reduction in the proportion

and absolute incidence of antibiotic-resistant pneumococci isolated from blood. Antibiotic resistance however emerged in non-vaccine-type pneumococci causing both ear infections and invasive disease following the 7-valent conjugate vaccine introduction in the USA, particularly among serotype 19A strains [192, 193]. The increase in serotype 19A post-conjugate vaccine in the USA was significantly increased among states with higher rates of community antimicrobial use in children [194]. In addition to direct protection of children from antibiotic-resistant pneumococci, and herd protection of adults to these resistant strains, through interruption of their transmission, conjugate vaccine may also contribute to reduction in selection of resistance by reducing the antimicrobial prescriptions written for vaccinated children, compared to controls [195–197].

## 12 Concluding Remarks

The multiply resistant pneumococcus continues to have a global distribution. Antimicrobial resistance within the pneumococcal population emerges and is maintained through a complex interplay of many factors. Attempts to reduce the burden of resistance in this pathogen are frustrated by widespread empiric therapy for respiratory infections. Both appropriate and inappropriate antibiotic uses continue to select resistance in this pathogen. Although the conjugate vaccine has reduced the burden of resistance in invasive isolates, continued antibiotic exposure is leading to the emergence of resistance in non-vaccine types.

## References

1. Fischer Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. *Lancet*. 2013;381:1405–16.
2. Castanheira M, Gales AC, Mendes RE, et al. Antimicrobial susceptibility of *Streptococcus pneumoniae* in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. *Clin Microbiol Infect*. 2004;10:645–51.
3. Reinert RR, Reinert S, van der Linden M, et al. Antimicrobial susceptibility of *Streptococcus pneumoniae* in eight European countries from 2001 to 2003. *Antimicrob Agents Chemother*. 2005;49:2903–13.
4. McGee L, McDougal L, Zhou J, et al. Nomenclature of major antimicrobial-resistant clones of *Streptococcus pneumoniae* defined by the pneumococcal molecular epidemiology network. *J Clin Microbiol*. 2001;39:2565–71.
5. Cardozo DM, Nascimento-Carvalho CM, Andrade AL, et al. Prevalence and risk factors for nasopharyngeal carriage of *Streptococcus pneumoniae* among adolescents. *J Med Microbiol*. 2008;57:185–9.
6. Dagan R, Melamed R, Muallem M, et al. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. *J Infect Dis*. 1996;174:1352–5.

7. Zenni MK, Cheatham SH, Thompson JM, et al. *Streptococcus pneumoniae* colonization in the young child: association with otitis media and resistance to penicillin. *J Pediatr*. 1995;127:533–7.
8. Mehr S, Wood N. *Streptococcus pneumoniae*—a review of carriage, infection, serotype replacement and vaccination. *Paediatr Resp Rev*. 2012;13:258–64.
9. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. *Lancet Infect Dis*. 2005;5:83–93.
10. Klugman KP, Friedland IR. Antibiotic-resistant pneumococci in pediatric disease. *Microb Drug Resist*. 1995;1:5–8.
11. Bronzwaer S, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. *Emerg Infect Dis*. 2002;8:278–82.
12. Van Eldere J, Mera RM, Miller LA, et al. Risk factors for development of multiple-class resistance to *Streptococcus pneumoniae* strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. *Antimicrob Agents Chemother*. 2007;51:3491–7.
13. Arason VA, Kristinsson KG, Sigurdsson JA, et al. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. *Br Med J*. 1996;313:387–91.
14. Levine OS, Farley M, Harrison LH, et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. *Pediatrics*. 1999;103:E28.
15. Samore MH, Magill MK, Alder SC, et al. High rates of multiple antibiotic resistance in *Streptococcus pneumoniae* from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. *Pediatrics*. 2001;108:856–65.
16. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. *Clin Infect Dis*. 2005;40:1288–97.
17. Dias R, Caniça M. Emergence of invasive erythromycin-resistant *Streptococcus pneumoniae* strains in Portugal: contribution and phylogenetic relatedness of serotype 14. *J Antimicrob Chemother*. 2004;54:1035–9.
18. Dagan R, Barkai G, Givon-Lavi N, et al. Seasonality of antibiotic-resistant *Streptococcus pneumoniae* that causes acute otitis media: a clue for an antibiotic-restriction policy? *J Infect Dis*. 2008;197:1094–102.
19. Feikin DR, Dowell SF, Nwanyanwu OC, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant *Streptococcus pneumoniae* in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. *J Infect Dis*. 2000;181:1501–5.
20. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. *N Engl J Med*. 1999;341:233–9.
21. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant *Streptococcus pneumoniae*: a case-control study. *Clin Infect Dis*. 2001;32:701–7.
22. Kupronis BA, Richards CL, Whitney CG, Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. *J Am Geriatr Soc*. 2003;51:1520–5.
23. von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacin-non-susceptible *Streptococcus pneumoniae* and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. *Lancet*. 2008;371:1108–13.
24. Mthwalo M, Wasas A, Huebner R, et al. Antimicrobial resistance of nasopharyngeal isolates of *Streptococcus pneumoniae* from children in Lesotho. *Bull WHO*. 1998;76:641–50.
25. Crowther-Gibson P, Cohen C, Klugman KP, et al. Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. *Antimicrob Agents Chemother*. 2012;56:5088–95.
26. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant *Streptococcus pneumoniae* in Atlanta. *N Engl J Med*. 1995;333:481–6.
27. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. *J Am Med Assoc*. 2001;286:49–56.
28. Bedos JP, Chevret S, Chastang C, et al. Epidemiological features of and risk factors for infection by *Streptococcus pneumoniae* strains with diminished susceptibility to penicillin: findings of a French survey. *Clin Infect Dis*. 1996;22:63–72.
29. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. *N Engl J Med*. 1978;299:735–40.
30. Soeters HM, von Gottberg A, Cohen C, et al. Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease. *Antimicrob Agents Chemother*. 2012;56:1602–5.
31. Buie KA, Klugman KP, von Gottberg A, et al. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. *J Infect Dis*. 2004;189:1996–2000.
32. Wyres KL, Lambertsen LM, Croucher NJ, et al. The multidrug-resistant PMEN1 pneumococcus is a paradigm for genetic success. *Genome Biol*. 2012;13:R103.
33. Corso A, Severina EP, Petruk VF, et al. Molecular characterisation of penicillin-resistant *Streptococcus pneumoniae* isolates causing respiratory disease in the United States. *Microb Drug Resist*. 1998;4:325–37.
34. Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant *Streptococcus pneumoniae* in the United States, 2004–2005. *Clin Infect Dis*. 2009;48:23–33.
35. Simões AS, Pereira L, Nunes S, et al. Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing *Pneumococci* in the PCV7 era in Portugal. *J Clin Microbiol*. 2011;49:2810–7.
36. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. *Science*. 2011;331:430–4.
37. Hiller NL, Eutsey RA, Powell E, et al. Differences in genotype and virulence among four multidrug-resistant *Streptococcus pneumoniae* isolates belonging to the PMEN1 clone. *PLoS ONE*. 2011;6:e28850.
38. Beall BW, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. *J Infect Dis*. 2011;203:1360–8.
39. Beall B, McEllistrem MC, Gertz Jr RE, et al. Pre- and post-vaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. *J Clin Microbiol*. 2006;44:999–1017.
40. Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of *Streptococcus pneumoniae* serotype 19A from children in the United States. *J Infect Dis*. 2005;192:1988–95.
41. Edson DC, Glick T, Massey LD. Susceptibility testing practices for *Streptococcus pneumoniae*: results of a proficiency testing survey of clinical laboratories. *Diagn Microbiol Infect Dis*. 2006;55:225–30.
42. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100–S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
43. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol*. 2007;45:2460–6.

44. Harris KA, Turner P, Green EA, et al. Duplex real-time PCR assay for detection of *Streptococcus pneumoniae* in clinical samples and determination of penicillin susceptibility. *J Clin Microbiol.* 2008;46:2751–8.
45. Srinivasan V, du Plessis M, Beall BW, et al. Quadriplex real-time polymerase chain reaction (*lytA*, *mef*, *erm*, *pbp2b*(wt)) for pneumococcal detection and assessment of antibiotic susceptibility. *Diagn Microbiol Infect Dis.* 2011;71:453–6.
46. Fukushima KY, Yanagihara K, Hirakata Y, et al. Rapid identification of penicillin and macrolide resistance genes and simultaneous quantification of *Streptococcus pneumoniae* in purulent sputum samples by use of a novel real-time multiplex PCR assay. *J Clin Microbiol.* 2008;46:2384–8.
47. Kearns AM, Graham C, Burdett D, et al. Rapid real-time PCR for determination of penicillin susceptibility in pneumococcal meningitis, including culture-negative cases. *J Clin Microbiol.* 2002;40:682–4.
48. Zettler EW, Scheibe RM, Dias CA, et al. Determination of penicillin resistance in *Streptococcus pneumoniae* isolates from southern Brazil by PCR. *Int J Infect Dis.* 2006;10:110–5.
49. Cassone M, D'Andrea MM, Iannelli F, et al. DNA microarray for detection of macrolide resistance genes. *Antimicrob Agents Chemother.* 2006;50:2038–41.
50. Haanperä M, Huovinen P, Jalava J. Detection and quantification of macrolide resistance mutations at positions 2058 and 2059 of the 23S rRNA gene by pyrosequencing. *Antimicrob Agents Chemother.* 2005;49:457–60.
51. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. *Ann Intern Med.* 1964;60:759–76.
52. Kislak JW, Razavi LM, Daly AK, et al. Susceptibility of pneumococci to nine antibiotics. *Am J Med Sci.* 1965;250:261–8.
53. Hansman D, Bullen MM. A resistant pneumococcus. *Lancet.* 1967;1:264–5.
54. Hansman D, Glasgow H, Sturt J, et al. Increased resistance to penicillin of pneumococci isolated from man. *N Engl J Med.* 1971;284:175–7.
55. Naraqi S, Kirkpatrick GP, Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. *J Pediatr.* 1974;85:671–3.
56. Appelbaum PC, Bhamjee A, Scragg JN, et al. *Streptococcus pneumoniae* resistant to penicillin and chloramphenicol. *Lancet.* 1977;2:995–7.
57. Hakenbeck R, Ellerbrok H, Briese T, et al. Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the (-lactam binding site). *Antimicrob Agents Chemother.* 1986;30:553–8.
58. Kell CM, Sharma UK, Dowson CG, et al. Deletion analysis of the essentiality of penicillin-binding proteins 1A, 2B and 2X of *Streptococcus pneumoniae*. *FEMS Microbiol Lett.* 1993;106:171–5.
59. Smith AM, Feldman C, Massidda O, et al. Altered PBP2A and its role in the development of penicillin, cefotaxime and ceftriaxone resistance in a clinical isolate of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2005;49:2002–7.
60. Reichmann P, Köning A, Marton A, et al. Penicillin-binding proteins as resistance determinants in clinical isolates of *Streptococcus pneumoniae*. *Microb Drug Resist.* 1996;2:177–81.
61. Hakenbeck R, Brückner R, Denapate D, et al. **Molecular mechanisms of  $\beta$ -lactam resistance in *Streptococcus pneumoniae*.** *Future Microbiol.* 2012;7:395–410.
62. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of *Streptococcus pneumoniae* are primary resistance determinants for different classes of  $\beta$ -lactam antibiotics. *Antimicrob Agents Chemother.* 1996;40:829–34.
63. Dowson CG, Johnson AP, Cercenado E, et al. Genetics of oxacillin resistance in clinical isolates of *Streptococcus pneumoniae* that are oxacillin resistant and penicillin susceptible. *Antimicrob Agents Chemother.* 1994;38:49–53.
64. Munoz R, Dowson CG, Daniels M, et al. Genetics of resistance to third-generation cephalosporins in clinical isolates of *Streptococcus pneumoniae*. *Mol Microbiol.* 1992;6:2461–5.
65. Coffey TJ, Daniels M, McDougal LK, et al. Genetic analysis of clinical isolates of *Streptococcus pneumoniae* with high-level resistance to expanded-spectrum cephalosporins. *Antimicrob Agents Chemother.* 1995;39:1306–13.
66. Smith AM, Klugman KP. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2001;45:2393–6.
67. Vanhoof R, Brouillard J, Damee S, et al. High prevalence of penicillin resistance and comparative in vitro activity of various antibiotics in clinical isolates of *Streptococcus pneumoniae* isolated in the Province of Hainaut during winter 2004. *Acta Clin Belg.* 2005;60:345–9.
68. Cafini F, del Campo R, Alou L, et al. Alterations of the penicillin-binding proteins and *murM* alleles of clinical *Streptococcus pneumoniae* isolates with high-level resistance to amoxicillin in Spain. *J Antimicrob Chemother.* 2006;57:224–9.
69. Butler DL, Gagnon RC, Miller LA, et al. Differences between the activity of penicillin, amoxicillin, and co-amoxiclav against 5,252 *Streptococcus pneumoniae* isolates tested in the Alexander Project 1992–1996. *J Antimicrob Chemother.* 1999;43:777–82.
70. Schrag SJ, McGee L, Whitney CG, et al. Emergence of *Streptococcus pneumoniae* with very-high-level resistance to penicillin. *Antimicrob Agents Chemother.* 2004;48:3016–23.
71. Doit C, Loukil C, Fitoussi F, et al. Emergence in France of multiple clones of clinical *Streptococcus pneumoniae* isolates with high-level resistance to amoxicillin. *Antimicrob Agents Chemother.* 1999;43:1480–3.
72. Kosowska K, Jacobs MR, Bajaksouzian S, et al. Alterations of penicillin-binding proteins 1A, 2X and 2B in *Streptococcus pneumoniae* isolates with amoxicillin MICs are higher than penicillin MICs. *Antimicrob Agents Chemother.* 2004;48:4020–2.
73. Du Plessis M, Bingen E, Klugman KP. Analysis of penicillin-binding protein genes of clinical isolates of *Streptococcus pneumoniae* with reduced susceptibility to amoxicillin. *Antimicrob Agents Chemother.* 2002;46:2349–57.
74. Gasc AM, Kauc L, Barraillé P, et al. Gene localization, size, and physical map of the chromosome of *Streptococcus pneumoniae*. *J Bacteriol.* 1991;173:7361–7.
75. Smith AM, Botha RF, Koornhof HJ, et al. Emergence of a pneumococcal clone with cephalosporin resistance and penicillin susceptibility. *Antimicrob Agents Chemother.* 2001;45:2648–50.
76. Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against *Streptococcus pneumoniae* isolates exhibiting high-level resistance to ceftriaxone. *Int J Antimicrob Agents.* 2012;39:534–8.
77. Flamm RK, Sader HS, Farrell DJ, et al. Antimicrobial activity of ceftaroline tested against drug-resistant subsets of *Streptococcus pneumoniae* from U.S. medical centers. *Antimicrob Agents Chemother.* 2014;58:2468–71.
78. McDougal LK, Rasheed JK, Biddle JW, et al. Identification of multiple clones of extended-spectrum cephalosporin-resistant *Streptococcus pneumoniae* isolates in the United States. *Antimicrob Agents Chemother.* 1995;39:2282–8.
79. Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of *Streptococcus pneumoniae* from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. *J Antimicrob Chemother.* 2002;50(Suppl S1):25–37.
80. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. *Emerg Infect Dis.* 2005;11:802–7.

81. Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among *Streptococcus pneumoniae* isolates 2001–2004. *J Infect.* 2007;55:111–8.
82. Weisblum B. Erythromycin resistance by ribosome modification. *Antimicrob Agents Chemother.* 1995;39:577–85.
83. Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A, et al. Identification of an *erm(A)* erythromycin resistance methylase gene in *Streptococcus pneumoniae* isolated in Greece. *Antimicrob Agents Chemother.* 2001;45:342–4.
84. Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of *Streptococcus pneumoniae* from the PROTEKT 1999–2000 study. *Antimicrob Agents Chemother.* 2003;47:1777–83.
85. Doktor SZ, Shortridge VD, Beyer JM, et al. Epidemiology of macrolide and/or lincosamide resistant *Streptococcus pneumoniae* clinical isolates with ribosomal mutations. *Diagn Microbiol Infect Dis.* 2004;49:47–52.
86. Davies TA, Bush K, Sahn D, et al. Predominance of 23S rRNA mutants among non-*erm*, non-*mef* macrolide-resistant clinical isolates of *Streptococcus pneumoniae* collected in the United States in 1999–2000. *Antimicrob Agents Chemother.* 2005;49:3031–3.
87. Farrell DJ, Jenkins SG. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among *Streptococcus pneumoniae* isolates collected from patients with respiratory tract infections: PROTEKT US 2001–2002. *J Antimicrob Chemother.* 2004;54(Suppl S1):17–22.
88. Cochetti I, Vecchi M, Mingoia M, et al. Molecular characterization of pneumococci with efflux-mediated erythromycin resistance and identification of a novel *mef* gene subclass, *mef(I)*. *Antimicrob Agents Chemother.* 2005;49:4999–5006.
89. Santagati M, Iannelli F, Cascone C, et al. The novel conjugative transposon Tn1207.3 carries the macrolide efflux gene *mef(A)* in *Streptococcus pyogenes*. *Microb Drug Resist.* 2003;9:243–7.
90. Gay K, Stephens DS. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in *Streptococcus pneumoniae*. *J Infect Dis.* 2001;184:56–65.
91. Mingoia M, Vecchi M, Cochetti I, et al. Composite structure of *Streptococcus pneumoniae* containing the erythromycin efflux resistance gene *mef(I)* and the chloramphenicol resistance gene *catQ*. *Antimicrob Agents Chemother.* 2007;51:3983–7.
92. McGee L, Klugman KP, Wasas A, et al. Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants (*erm(B)* and *mef(A)*) in South Africa. *Antimicrob Agents Chemother.* 2001;45:1595–8.
93. Farrell DJ, Jenkins SG, Brown SD, et al. Emergence and spread of *Streptococcus pneumoniae* with *erm(B)* and *mef(A)* resistance. *Emerg Infect Dis.* 2005;11:851–8.
94. Bowers JR, Driebe EM, Nibecker JL, et al. Dominance of multi-drug resistant CC271 clones in macrolide-resistant *Streptococcus pneumoniae* in Arizona. *BMC Microbiol.* 2012;12:12.
95. Patel SN, McGeer A, Melano R, et al. Susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. *Antimicrob Agents Chemother.* 2011;55:3703–8.
96. Simoens S, Verhaegen J, van Bleyenbergh P, et al. Consumption patterns and in vitro resistance of *Streptococcus pneumoniae* to fluoroquinolones. *Antimicrob Agents Chemother.* 2011;55:3051–3.
97. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive *Streptococcus pneumoniae* serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. *J Clin Microbiol.* 2009;47:1012–20.
98. Wolter N, du Plessis M, von Gottberg A, et al. Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa. *J Clin Microbiol.* 2009;47:1319–24.
99. Ho PL, Yam WC, Cheung TK, et al. Fluoroquinolone resistance among *Streptococcus pneumoniae* in Hong Kong linked to the Spanish 23F clone. *Emerg Infect Dis.* 2001;7:906–8.
100. Pan XS, Ambler J, Mehtar S, et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1996;40:2321–6.
101. Bast DJ, Low DE, Duncan CL, et al. Fluoroquinolone resistance in clinical isolates of *Streptococcus pneumoniae*: contributions of type II topoisomerase mutations and efflux to levels of resistance. *Antimicrob Agents Chemother.* 2000;44:3049–54.
102. Lim S, Bast D, McGeer A, et al. Antimicrobial susceptibility breakpoints and first-step *parC* mutations in *Streptococcus pneumoniae*: redefining fluoroquinolones resistance. *Emerg Infect Dis.* 2003;9:833–7.
103. Li X, Zhao X, Drlica K. Selection of *Streptococcus pneumoniae* mutants having reduced susceptibility to moxifloxacin and levofloxacin. *Antimicrob Agents Chemother.* 2002;46:522–4.
104. Gillespie SH, Voelker LL, Ambler JE, et al. Fluoroquinolone resistance in *Streptococcus pneumoniae*: evidence that *gyrA* mutations arise at a lower rate and that mutation in *gyrA* or *parC* predisposes to further mutation. *Microb Drug Resist.* 2003;9:17–24.
105. Perichon B, Tankovic J, Courvalin P. Characterization of a mutation in the *parE* gene that confers fluoroquinolone resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1997;41:1166–7.
106. Weigel LM, Anderson GJ, Facklam RR, et al. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2001;45:3517–23.
107. Duesberg CB, Welte T, Pletz MW. The Lys137Asn mutation as surrogate marker for developing fluoroquinolone resistance in *Streptococcus pneumoniae*. *J Chemother.* 2007;19:750–1.
108. Pletz MW, Fugit RV, McGee L, et al. Fluoroquinolone-resistant *Streptococcus pneumoniae*. *Emerg Infect Dis.* 2006;12:1462–3.
109. Zeller V, Janoir C, Kitzis MD, et al. Active efflux as a mechanism of resistance to ciprofloxacin in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1997;41:1973–8.
110. Pletz MW, van der Linden M, von Baum H, et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in *Streptococcus pneumoniae* from patients with community-acquired pneumonia despite high fluoroquinolone usage. *Int J Med Microbiol.* 2011;301:53–7.
111. Andersen CL, Holland IB, Jacq A. Verapamil, a Ca<sup>2+</sup> channel inhibitor acts as a local anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in *E. coli*. *Biochim Biophys Acta.* 2006;1758:1587–95.
112. Pletz MW, Michaylov N, Schumacher U, et al. Antihypertensives suppress the emergence of fluoroquinolone-resistant mutants in pneumococci: an in vitro study. *Int J Med Microbiol.* 2013;303:176–81.
113. Janoir C, Podglajen I, Kitzis MD, et al. In vitro exchange of fluoroquinolone resistance determinants between *Streptococcus pneumoniae* and viridans streptococci and genomic organization of the *parE-parC* region in *S. mitis*. *J Infect Dis.* 1999;180:555–8.
114. Tankovic J, Perichon B, Duval J, et al. Contribution of mutations in *gyrA* and *parC* genes to fluoroquinolone resistance of mutants of *Streptococcus pneumoniae* obtained in vivo and in vitro. *Antimicrob Agents Chemother.* 1996;40:2505–10.
115. Martin-Galiano AJ, Balsalobre L, Fenoll A, et al. Genetic characterization of optochin-susceptible viridans group streptococci. *Antimicrob Agents Chemother.* 2003;47:3187–94.
116. Bast DJ, de Azavedo JC, Tam TY, et al. Interspecies recombination contributes minimally to fluoroquinolone resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2001;45:2631–4.
117. Pletz MW, McGee L, Beall B, et al. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive *Streptococcus pneumoniae* isolates in the United States. *Antimicrob Agents Chemother.* 2005;49:779–80.

118. Balsalobre L, Ferrandiz MJ, Linares J, et al. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 2003;47:2072–81.
119. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive *Streptococcus pneumoniae* in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. *Antimicrob Agents Chemother*. 2004;48:3491–7.
120. Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant *Streptococcus pneumoniae*: data from the global PROTEKT surveillance programme. *J Antimicrob Chemother*. 2003;52:944–52.
121. Hsueh PR, Teng LJ, Lee CM, et al. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of *Streptococcus pyogenes*: SMART Program 2001 Data. *Antimicrob Agents Chemother*. 2003;47:2152–7.
122. Montanari MP, Tili E, Cochetti I, et al. Molecular characterization of clinical *Streptococcus pneumoniae* isolates with reduced susceptibility to fluoroquinolones emerging in Italy. *Microb Drug Resist*. 2004;10:209–17.
123. Lonks JR, Goldman DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. *Clin Infect Dis*. 2005;40:1657–64.
124. McGhee P, Clark C, Kosowska-Shick KM, et al. In vitro activity of CEM-101 against *Streptococcus pneumoniae* and *Streptococcus pyogenes* with defined macrolide resistance mechanisms. *Antimicrob Agents Chemother*. 2010;54:230–8.
125. Wilson DN. On the specificity of antibiotics targeting the large ribosomal subunit. *Ann NY Acad Sci*. 2011;1241:1–16.
126. Patel SN, Pillai DR, Pong-Porter S, et al. In vitro activity of ceftriaxone, ceftibiprole and cethromycin against clinical isolates of *Streptococcus pneumoniae* collected from across Canada between 2003 and 2008. *J Antimicrob Chemother*. 2009;64:659–60.
127. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 2002;46:2727–34.
128. Walsh F, Willcock J, Amyes S. High-level telithromycin resistance in laboratory-generated mutants of *Streptococcus pneumoniae*. *J Antimicrob Chemother*. 2003;52:345–53.
129. Farrell DJ, Morrissey I, Bakker S, et al. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against *Streptococcus pneumoniae* with macrolide resistance due to ribosomal mutations. *Antimicrob Agents Chemother*. 2004;48:3169–71.
130. Reinert RR, van der Linden M, Al-Lahham A. Molecular characterization of the first telithromycin-resistant *Streptococcus pneumoniae* isolate in Germany. *Antimicrob Agents Chemother*. 2005;49:3520–2.
131. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of *Streptococcus pneumoniae* from Eastern Europe and North America. *Antimicrob Agents Chemother*. 2000;44:3395–401.
132. Faccione D, Andres P, Galas M, et al. Emergence of a *Streptococcus pneumoniae* clinical isolate highly resistant to telithromycin and fluoroquinolones. *J Clin Microbiol*. 2005;43:5800–3.
133. Pérez-Trallero E, Marimon JM, Iglesias L, et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. *Emerg Infect Dis*. 2003;9:1159–62.
134. Wolter N, Smith AM, Low DE, et al. High-level telithromycin resistance in a clinical isolate of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 2007;51:1092–5.
135. Draghi DC, Sheehan DJ, Hogan P, et al. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. *Antimicrob Agents Chemother*. 2005;49:5024–32.
136. Flamm RK, Mendes RE, Ross JE, et al. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. *Diagn Microbiol Infect Dis*. 2013;76:206–13.
137. Flamm RK, Mendes RE, Ross JE, et al. Linezolid surveillance results for the United States: LEADER surveillance program 2011. *Antimicrob Agents Chemother*. 2013;57:1077–81.
138. Meka VG, Gold HS. Antimicrobial resistance to linezolid. *Clin Infect Dis*. 2004;39:1010–5.
139. Wolter N, Smith AM, Farrell DJ, et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. *Antimicrob Agents Chemother*. 2005;49:3554–7.
140. Dong W, Chochua S, McGee L, et al. Mutations within the *rpID* gene of linezolid nonsusceptible *Streptococcus pneumoniae* strains isolated in the USA. *Antimicrob Agents Chemother*. 2014;58:2459–62.
141. Feng J, Lupien A, Gingras H, et al. Genome sequencing of linezolid-resistant *Streptococcus pneumoniae* mutants reveals novel mechanisms of resistance. *Genome Res*. 2009;19:1214–23.
142. Feng J, Billal DS, Lupien A, et al. Proteomic and transcriptomic analysis of linezolid resistance in *Streptococcus pneumoniae*. *J Proteome Res*. 2011;10:4439–52.
143. Kisgen JJ, Mansour H, Unger NR, et al. Tedizolid: a new oxazolidinone antimicrobial. *Am J Health Syst Pharm*. 2014;71:621–33.
144. Jones RN, Farrell DJ, Morrissey I. Quinupristin-dalfopristin resistance in *Streptococcus pneumoniae*: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. *Antimicrob Agents Chemother*. 2003;47:2696–8.
145. Wyres KL, van Tonder A, Lamberts LM, et al. Evidence of antimicrobial resistance-conferring genetic elements among pneumococci isolated prior to 1974. *BMC Genomics*. 2013;14:500.
146. Burdett V, Inamine J, Rajagopalan S. Heterogeneity of tetracycline resistance determinants in *Streptococcus*. *J Bacteriol*. 1982;149:995–1004.
147. Widdowson CA, Klugman KP, Hanslo D. Identification of the tetracycline resistance gene, *tet(O)*, in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 1996;40:2891–3.
148. Oggioni MR, Dowson CG, Smith JM, et al. The tetracycline resistance gene *tet(M)* exhibits mosaic structure. *Plasmid*. 1996;35:156–63.
149. Doherty N, Trzcinski K, Pickerill P, et al. Genetic diversity of the *tet(M)* gene in tetracycline-resistant clonal lineages of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 2000;44:2979–84.
150. Dzierzanowska-Fangrat K, Senczuk K, Gorska P, et al. Evidence for tetracycline resistance determinant *tet(M)* allele replacement in a *Streptococcus pneumoniae* population of limited geographical origin. *Int J Antimicrob Agents*. 2006;27:159–64.
151. Doern GV, Brueggemann A, Holley Jr HP, et al. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the winter months of 1994–1995: results of a 30-center national surveillance study. *Antimicrob Agents Chemother*. 1996;40:1208–13.
152. Marchese A, Mannelli S, Tonoli E, et al. Prevalence of antimicrobial resistance in *Streptococcus pneumoniae* circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997–1999). *Microb Drug Resist*. 2001;7:277–87.
153. Padayachee T, Klugman KP. Molecular basis of rifampin resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 1999;43:2361–5.
154. Ferrandiz MJ, Ardanuy C, Linares J, et al. New mutations and horizontal transfer of *rpoB* among rifampin-resistant *Streptococcus pneumoniae* from four Spanish hospitals. *Antimicrob Agents Chemother*. 2005;49:2237–45.
155. Ayoubi P, Kilic AO, Vijayakumar MN. *Tn5253*, the pneumococcal omega (*cat tet*) BM6001 element, is a composite structure of two



- conjugative transposons, *Tn5251* and *Tn5252*. *J Bacteriol.* 1991;173:1617–22.
156. Widdowson CA, Adrian PV, Klugman KP. Acquisition of chloramphenicol resistance by the linearization and integration of the entire staphylococcal plasmid pC194 into the chromosome of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2000;44:393–5.
  157. Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis*: a European multicenter study during 2000–2001. *Clin Microbiol Infect.* 2003;9:590–9.
  158. Johnson DM, Stilwell MG, Fritsche TR, et al. Emergence of multidrug-resistant *Streptococcus pneumoniae*: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). *Diagn Microbiol Infect Dis.* 2006;56:69–74.
  159. Adrian PV, Klugman KP. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1997;41:2406–13.
  160. Maskell JP, Sefton AM, Hall LM. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2001;45:1104–8.
  161. Lopez P, Espinosa M, Greenberg B, et al. Sulfonamide resistance in *Streptococcus pneumoniae*: DNA sequence of the gene encoding dihydropteroate synthase and characterization of the enzyme. *J Bacteriol.* 1987;169:4320–6.
  162. Maskell JP, Sefton AM, Hall LM. Mechanism of sulfonamide resistance in clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1997;41:2121–6.
  163. Padayachee T, Klugman KP. Novel expansions of the gene encoding dihydropteroate synthase in trimethoprim-sulfamethoxazole-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1999;43:2225–30.
  164. Feldman C, Kallenbach JM, Miller SD, et al. Community-acquired pneumonia due to penicillin-resistant pneumococci. *N Engl J Med.* 1985;313:615–7.
  165. Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. *N Engl J Med.* 1987;317:18–22.
  166. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. *Chest.* 1997;112:1657–64.
  167. Kaplan SL, Mason Jr EO, Barson WJ, et al. Outcome of invasive infections outside the central nervous system caused by *Streptococcus pneumoniae* isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. *Pediatr Infect Dis J.* 2001;20:392–6.
  168. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. *Am J Med.* 2002;113:120–6.
  169. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. *Clin Infect Dis.* 2003;37:230–7.
  170. Daum RS, Nachman JP, Leitch CD, et al. Nosocomial epiglottitis associated with penicillin- and cephalosporin-resistant *Streptococcus pneumoniae* bacteremia. *J Clin Microbiol.* 1994;32:246–8.
  171. Dagan R, Leibovitz E, Fliess DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. *Antimicrob Agents Chemother.* 2000;44:43–50.
  172. Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. *Lancet Infect Dis.* 2002;2:593–604.
  173. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. *Pediatr Infect Dis J.* 2001;20:829–37.
  174. Brook I, Gooch WMI, et al. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. *Ann Otol Rhinol Laryngol.* 2000;109:2–20.
  175. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. *Lancet.* 1992;339:405–8.
  176. Klugman KP, Walsh AL, Phiri A, et al. Mortality in penicillin-resistant pneumococcal meningitis. *Pediatr Infect Dis J.* 2008;27:671–2.
  177. Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by *Streptococcus pneumoniae* with reduced susceptibility to beta-lactam antibiotics. *Pediatr Infect Dis J.* 1991;10:871–3.
  178. Klugman KP. Pneumococcal resistance to the third-generation cephalosporins: clinical, laboratory and molecular aspects. *Int J Antimicrob Agents.* 1994;4:63–7.
  179. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant *Streptococcus pneumoniae* in cerebrospinal fluid of children with acute bacterial meningitis. *Antimicrob Agents Chemother.* 1995;39:1988–92.
  180. Friedland IR, Klugman KP. Cerebrospinal fluid bactericidal activity against cephalosporin-resistant *Streptococcus pneumoniae* in children with meningitis treated with high-dosage cefotaxime. *Antimicrob Agents Chemother.* 1997;41:1888–91.
  181. Musher DM, Dowell ME, Shorridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. *N Engl J Med.* 2002;346:630–1.
  182. Daneman N, McGeer A, Green K, et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. *Clin Infect Dis.* 2006;43(4):432–8.
  183. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant *Streptococcus pneumoniae*. *Clin Infect Dis.* 2002;35:556–64.
  184. Jacobs MR, Bajaksouzian S, Windau A, et al. Susceptibility of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U S Surveillance Study. *Clin Lab Med.* 2004;24:503–30.
  185. Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. *Pediatr Infect Dis J.* 2001;20:260–4.
  186. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. *N Engl J Med.* 2002;346:747–50.
  187. Anderson KB, Tan JS, File Jr TM, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. *Clin Infect Dis.* 2003;37:376–81.
  188. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med.* 2003;348:1737–46.
  189. Pishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis.* 2010;201(1):32–41.
  190. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *N Engl J Med.* 2003;349:1341–8.
  191. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Engl J Med.* 2006;354:1455–63.
  192. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. *J Am Med Assoc.* 2007;298(15):1772–8.

193. Moore MR, Gertz Jr RE, Woodbury RL, et al. Population snapshot of emergent *Streptococcus pneumoniae* serotype 19A in the United States, 2005. *J Infect Dis.* 2008;197(7):1016–27.
194. Hicks LA, Chien YW, Taylor Jr TH, et al. Outpatient antibiotic prescribing and nonsusceptible *Streptococcus pneumoniae* in the United States, 1996–2003. *Clin Infect Dis.* 2011;53(7):631–9.
195. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. *Pediatr Infect Dis J.* 2003;22(1):10–6.
196. Dagan R, Sikuler-Cohen M, Zamir O, et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. *Pediatr Infect Dis J.* 2001;20(10):951–8.
197. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. *Lancet Infect Dis.* 2014;14:205–12.

Nainee Desai, Judith Steenbergen, and David E. Katz

---

## 1 Introduction

The taxonomy of streptococci has undergone major changes during the last two decades. The present classification is based on both phenotypic and genotypic data. Phylogenetic classification of streptococci is based on 16S rRNA sequences [1], and it forms the backbone of the overall classification system of streptococci. Phenotypic properties are also important, especially for clinical microbiologists. The type of hemolysis on blood agar, reaction with Lancefield grouping antisera, resistance to optochin, and bile solubility remain important for grouping of clinical *Streptococcus* isolates and therefore treatment options [2]. In the following chapter, two phenotypic classification groups, viridans group streptococci (VGS) and beta-hemolytic streptococci, will be discussed.

Antimicrobial resistance is common among VGS and beta-hemolytic streptococci isolates. Beta-lactam resistance is widespread among VGS, and resistance rates to other antimicrobials are continuously increasing. Beta-lactam resistance is uncommon in beta-hemolytic streptococci. Macrolide resistance, however, presents a clinical concern in the outpatient setting. High-level beta-lactam resistance in VGS is a real threat to the treatment of infective endocarditis and empirical treatment of sepsis in neutropenic patients. Treatment of infections, including pharyngitis, caused by macrolide-resistant beta-hemolytic streptococci may also become challenging if resistance rates continue to rise.

---

N. Desai, Pharm.D. (✉)  
Medical Affairs Department, Cubist Pharmaceuticals,  
65 Hayden Avenue, Lexington, MA 02421, USA  
e-mail: [Nainee.Desai@cubist.com](mailto:Nainee.Desai@cubist.com)

J. Steenbergen, Ph.D.  
Clinical Microbiology Department, Cubist Pharmaceuticals,  
Lexington, MA, USA

D.E. Katz, M.D., M.P.H.  
Internal Medicine Department 'D', Shaare Zedek Medical Center,  
Hebrew University Hadassah Medical Center, Jerusalem, Israel

Infections caused by Gram-positive organisms have increased in frequency over time and are almost as common as Gram-negative infections. This has been linked to greater use of invasive procedures and the increasing proportion of hospital-acquired infection. The regular use of broad-spectrum antibiotics in increasingly sick patients has likely resulted in increased bacterial resistance over time [3]. As a result, implementation of antimicrobial stewardship and infection control processes has become progressively more important in protecting patients, health-care providers, and communities.

This chapter summarizes the general characteristics of the streptococci groups, the current antimicrobial resistance trends, resistance mechanisms, and the clinical implication of resistance for viridans and beta-hemolytic streptococci.

---

## 2 Characteristics of Non-pneumococcal Streptococci

### 2.1 Viridans Group Streptococci

Viridans group streptococci form a phylogenetically heterogeneous group of species belonging to the genus *Streptococcus* [1]. However, they have some common phenotypic properties. VGS are a group of catalase-negative, Gram-positive cocci with a chaining morphology upon microscopic examination. They can be grouped as alpha- or nonhemolytic. They can be differentiated from *S. pneumoniae* by their resistance to optochin and lack of bile solubility, though the distinction between the two groups remains difficult due to similar sequence homology [2, 4]. They are leucine aminopeptidase positive, pyrrolidonylaryl amidase negative, and can be differentiated from *Enterococcus* species by their inability to grow in medium containing 6.5% sodium chloride [2]. Nutritionally variant streptococci were once included in VGS but based on molecular data been removed to a new genus *Abiotrophia* [5]. VGS belong to the normal microbiota of the oral cavities and upper respiratory tracts of humans and animals. They can also be isolated from